[
    {
        "id": "58",
        "PMID": "10547391",
        "title": "\nRandomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer",
        "journal": "J Natl Cancer Inst",
        "abstract": "Background:\nTreatment A has been shown to inhibit breast carcinogenesis in preclinical studies. We determined the efficacy of treatment A in preventing a second breast malignancy in women with breast cancer.\nMethods:\nWe randomly assigned 2972 women, aged 30\u201070 years, with surgically removed stage I breast cancer or ductal carcinoma in situ to receive for 5 years either treatment A orally (200 mg/day) (n=1496) or no treatment (n = 1476). Random assignment of patients was centrally managed by the coordinating center in Milan. All women were followed by use of the same procedures throughout the study period, and the radiologists who examined the mammograms were blinded to the allocated treatment arm. The primary end point was the incidence of contralateral breast cancer or ipsilateral breast cancer 7 years after randomization. The hazards of breast cancer occurrence were determined by Cox proportional hazards regression analysis. Statistical tests were two\u2010sided.\nResults:\n2867 assessable women were included in the analyses (1432 in the treatment A arm and 1435 in the control arm). At a median observation time of 97 months, there were no statistically significant differences in the occurrence of contralateral breast cancer (65 events in the treatment A arm versus 71 in the control arm; hazard ratio [HR] = 0.92; 95% confidence interval [CI] = 0.66\u20101.29; P = .642) or ipsilateral breast cancer (treatment A group = 100 events; control group = 121 events; HR = 0.83; 95% CI = 0.64\u20101.09; P = .177) between the two arms. There were no statistically significant differences between the two arms in tumors in other organs (38 in the treatment A arm versus 40 in the control arm), incidence of distant metastasis (HR = 0.98; 95% CI = 0.79\u20101.22; P = .858), and all\u2010cause mortality (HR = 1.16; 95% CI = 0.92\u20101.48; P = .215).\nConclusion:\nTreatment A was not more effective than no treatment in preventing a second breast malignancy in women with breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nScientists wanted to see if a medicine called Treatment A could help prevent women who had breast cancer from getting another breast cancer. They took 2,972 women who had already had surgery for early-stage breast cancer and split them into two groups. One group took Treatment A every day for five years, and the other group didn\u2019t take any treatment.\n\nAfter following the women for about 8 years, the scientists looked at how many women in each group got breast cancer again. They found that there wasn\u2019t a big difference between the two groups. The women who took Treatment A didn\u2019t have fewer cases of new breast cancer compared to those who didn\u2019t take it.\n\nIn the end, the study showed that Treatment A didn\u2019t work better than doing nothing to stop a second breast cancer from happening. So, the scientists concluded that this treatment wasn\u2019t helpful for these women."
    },
    {
        "id": "57",
        "PMID": "10547391",
        "title": "\nRandomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer",
        "journal": "J Natl Cancer Inst",
        "abstract": "Background:\nTreatment A has been shown to inhibit breast carcinogenesis in preclinical studies. We determined the efficacy of treatment A in preventing a second breast malignancy in women with breast cancer.\nMethods:\nWe randomly assigned 2972 women, aged 30\u201070 years, with surgically removed stage I breast cancer or ductal carcinoma in situ to receive for 5 years either treatment A orally (200 mg/day) or no treatment. The primary end point was the incidence of contralateral breast cancer or ipsilateral breast cancer 7 years after randomization. Other end points considered post hoc were the same outcomes stratified by menopausal status, incidence of distant metastases, overall mortality, and tumors in other organs. The hazards of breast cancer occurrence were determined by Cox proportional hazards regression analysis. Statistical tests were two\u2010sided.\nResults:\nAt a median observation time of 97 months, there were no statistically significant differences in the occurrence of contralateral breast cancer (P =.642) or ipsilateral breast cancer (P =.177) between the two arms. However, an interaction was detected between treatment A and menopausal status in both outcomes (P for interaction in both outcomes =.045), with a possible beneficial effect in premenopausal women (contralateral breast cancer: adjusted hazard ratio [HR] = 0.66, and 95% confidence interval [CI] = 0.41\u20101.07; ipsilateral breast cancer: adjusted HR = 0.65, and 95% CI = 0.46\u20100. 92) and an opposite effect in postmenopausal women (contralateral breast cancer: adjusted HR = 1.32, and 95% CI = 0.82\u20102.15; ipsilateral breast cancer: adjusted HR = 1.19, and 95% CI = 0.75\u20101. 89). There were no statistically significant differences between the two arms in tumors in other organs, incidence of distant metastasis, and all\u2010cause mortality.\nConclusion:\nTreatment A of women with breast cancer for 5 years appears to have no statistically significant effect on the incidence of second breast malignancies overall, although a possible benefit was detected in premenopausal women. These studies, particularly the post hoc analyses, are considered exploratory and need to be confirmed.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nScientists wanted to see if a medicine called Treatment A could help prevent women who had breast cancer from getting another breast cancer. They studied 2,972 women who had already had surgery for early-stage breast cancer. Half of the women took Treatment A every day for five years, and the other half did not take any medicine.\n\nAfter about 8 years, the scientists looked at how many women got another breast cancer. They found that there wasn\u2019t a big difference between the two groups. This means that Treatment A didn\u2019t really help most women avoid getting another breast cancer.\n\nHowever, they noticed something interesting: it seemed like Treatment A might help younger women (those who hadn\u2019t gone through menopause yet) a little bit, but it might not help older women and could even make things worse for them.\n\nIn the end, the scientists said that while they found some hints that Treatment A could help younger women, they need to do more studies to be sure. They also warned that sometimes people can make results sound better than they really are, so we should be careful about how we understand these findings."
    },
    {
        "id": "46",
        "PMID": "10637238",
        "title": "Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nIt is uncertain whether treatment A provides additional benefit compared with chemotherapy alone. This trial was initiated to explore this question.\nPatients and methods:\nBetween January 1988 and December 1992, 231 patients with metastatic breast cancer were randomized to receive chemotherapy alone or treatment A + chemotherapy as front\u2010line therapy for metastatic breast cancer. Patients who experienced a complete response to induction therapy either received or did not receive maintenance treatment as a secondary randomization. The two end points of interest for this study were time to treatment failure (TTF) and survival time.\nResults:\nMedian survival was 30.0 months for chemotherapy alone and 29.3 months treatment A and chemotherapy, p=0.834. Time to treatment failure (TTF) was 13.4 months for patients who received treatment A + chemotherapy compared with 10.3 month for chemotherapy alone patients (P = .087). The response rates (complete response and partial response) was 69.2% of for patients who received chemotherapy alone and 68.9% for patients who received treatment A + chemotherapy, P =.99. There was no significant difference in toxicities seen between the two arms of the study. There were four lethal toxicities. Three infectious deaths occurred in patients receiving treatment A with chemotherapy.\nConclusion:\nIn patients with metastatic breast cancer, treatment A with chemotherapy was not more effective than chemotherapy alone.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose:** The study wanted to find out if a new treatment (let's call it Treatment A) helps people with a type of cancer called metastatic breast cancer when used with regular chemotherapy (the standard cancer treatment).\n\n**What They Did:** From 1988 to 1992, doctors looked at 231 patients with this cancer. They randomly split the patients into two groups: one group got just chemotherapy, and the other group got Treatment A along with chemotherapy. They also checked what happened to patients who got better after the first treatment to see if they needed more treatment. The researchers wanted to know how long it took for the treatment to stop working and how long the patients lived.\n\n**Results:** The study found that patients who got just chemotherapy lived for about 30 months, while those who got Treatment A plus chemotherapy lived for about 29 months. So, there wasn\u2019t much difference in how long they lived. However, the patients who got Treatment A plus chemotherapy had their treatment stop working after about 13.4 months, while those who got just chemotherapy had it stop working after about 10.3 months. This means Treatment A might have helped a little bit, but it wasn\u2019t a big difference. The number of patients who got better was almost the same in both groups, and there were no major side effects that were worse in one group compared to the other.\n\n**Conclusion:** In the end, the"
    },
    {
        "id": "45",
        "PMID": "10637238",
        "title": "Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nIt is uncertain whether treatment A provides additional benefit compared with chemotherapy alone. This trial was initiated to explore this question.\nPatients and methods:\nBetween January 1988 and December 1992, 231 patients with estrogen receptor (ER)\u2010positive or ER\u2010unknown metastatic breast cancer were randomized to receive chemotherapy alone or treatment A + chemotherapy as front\u2010line therapy for metastatic breast cancer. Patients who experienced a complete response to induction therapy either received or did not receive maintenance treatment as a secondary randomization.\nResults:\nThe response rates (complete response and partial response) of patients who received chemotherapy alone and treatment A + chemotherapy were similar (69.2% v 68.9%, respectively; P =.99). Time to treatment failure (TTF) was slightly longer for patients who received treatment A + chemotherapy compared with chemotherapy alone patients (13.4 months v 10.3 months, respectively; P =.087), and TTF was significantly longer in ER\u2010positive compared with ER\u2010negative patients (17.4 months v 10.3 months, respectively; P =.048). However, ER status had no effect on overall survival (30.0 months for chemotherapy alone v 29.3 months for treatment A + chemotherapy).\nConclusion:\nIn patients with potentially hormone\u2010sensitive metastatic breast cancer, treatment A + chemotherapy prolongs TTF for ER\u2010positive patients without improving overall survival.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose:** The study wanted to find out if a new treatment (let's call it Treatment A) helps people with a certain type of breast cancer more than just using regular chemotherapy (a common cancer treatment).\n\n**What They Did:** From 1988 to 1992, they looked at 231 patients who had breast cancer that might respond to hormone treatment. They split these patients into two groups: one group got only chemotherapy, and the other group got both Treatment A and chemotherapy. They also checked what happened to patients who got better after the first treatment.\n\n**What They Found:** \n- Both groups had similar success rates in getting better (about 69% for both).\n- Patients who got Treatment A and chemotherapy took a little longer before their treatment stopped working (13.4 months) compared to those who only got chemotherapy (10.3 months).\n- However, the type of breast cancer (whether it was hormone-sensitive or not) didn\u2019t change how long the patients lived overall. Both groups lived about the same time (around 30 months).\n\n**Conclusion:** For patients with a certain type of breast cancer, Treatment A plus chemotherapy helped them last a bit longer before the treatment stopped working, but it didn\u2019t help them live longer overall.\n\n**Important Note:** Sometimes, studies can be tricky. They might highlight small benefits to make a treatment sound better than it really is. So, we should be careful"
    },
    {
        "id": "27",
        "PMID": "11261827",
        "title": "Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer",
        "journal": "Breast Cancer Res Treat",
        "abstract": "Purpose:\nEfficacy and safety of treatment A was compared with comparator B in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer.\nMethods and materials:\nThe study was a prospective double\u2010blind randomized trial. All treated patients presented with positive estrogen receptors. Main end points were response rates, toxicity profile analysis, time to progression and survival. WHO and ECOG criteria were employed for response evaluation while toxicity was assessed according to WHO guidelines. Curves were constructed by means of Kaplan\u2010Meier methodology and were compared by means of log\u2010rank test.\nResults:\nFrom January 1996 to January 1999 a total of 217 patients were included in the study (106 in the treatment A and 111 in the comparator B). Both groups of patients were homogeneous regarding the main prognostic factors. A response rate of 64% (68/106) was observed in the treatment A group as compared with a 52% (58/111) in the comparator B group. Median times to progression and overall survival were not significantly different. A lower incidence of undesirable effects was appreciated in the treatment A arm.\nConclusion:\nOur data suggest that treatment A is an efficient and well\u2010tolerated agent for the therapy of postmenopausal women with hormonal positive receptors advanced breast cancer, and must be considered an alternative to comparator B as first line therapy for ER+ advanced breast cancer patients and as well as an adjuvant treatment.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\nThis passage talks about a study that looked at two different treatments for women who have a type of breast cancer called advanced breast cancer. The women in the study had not received any other treatments before. \n\nThe researchers wanted to see if Treatment A was better or safer than Treatment B. They did a special kind of study where neither the doctors nor the patients knew which treatment they were getting (this is called a double-blind study). They checked how well the treatments worked, how they affected the patients, and how long the patients lived after starting the treatment.\n\nIn the study, 217 women participated, with 106 getting Treatment A and 111 getting Treatment B. They found that more women responded well to Treatment A (64 out of 106) compared to Treatment B (58 out of 111). However, the time until the cancer got worse and how long the women lived were similar for both treatments. Treatment A also had fewer bad side effects.\n\nThe researchers concluded that Treatment A is a good option for these women and could be used instead of Treatment B. \n\nHowever, it\u2019s important to be careful when reading about studies like this because sometimes the results can be presented in a way that makes one treatment seem better than it really is. So, we should think critically about what the study is saying."
    },
    {
        "id": "28",
        "PMID": "11261827",
        "title": "Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer",
        "journal": "Breast Cancer Res Treat",
        "abstract": "Purpose:\nEfficacy and safety of treatment A was compared with comparator B in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer.\nMethods and materials:\nThe study was a prospective double\u2010blind randomized trial. All treated patients presented with positive estrogen receptors. Main end points were response rates, toxicity profile analysis, time to progression and survival. WHO and ECOG criteria were employed for response evaluation while toxicity was assessed according to WHO guidelines. Curves were constructed by means of Kaplan\u2010Meier methodology and were compared by means of log\u2010rank test.\nResults:\nFrom January 1996 to January 1999 a total of 217 patients were included in the study (106 in the treatment A and 111 in the comparator B). Both groups of patients were homogeneous regarding the main prognostic factors. Response rates were not statistically different between the two therapeutic arms. A response rate of 64% (68/106) was observed in the treatment A group as compared with a 52% (58/111) in the comparator B group. Median times to progression (hazard ratios (HR) = 1.016; 95% CI 0.80\u20101.32; p=0.823) and overall survival (HR = 0.97 (95% CI 0.74\u20101.29; p=0.532) were not statistically significantly different. A lower incidence of undesirable effects was appreciated in the treatment A arm.\nConclusion:\nTreatment A was not more effective than comparator B in postmenopausal women with advanced breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose:** The study wanted to see if a new medicine (called treatment A) was better and safer than another medicine (called comparator B) for women who have a type of breast cancer and have not been treated for it before.\n\n**Methods:** The researchers did a special kind of study where neither the doctors nor the patients knew which medicine they were getting (this is called a double-blind study). They looked at women who had a certain type of breast cancer that responds to hormones. They measured how well the medicines worked, how safe they were, and how long the women lived after starting the treatment.\n\n**Results:** From 1996 to 1999, 217 women took part in the study. Some got treatment A, and some got comparator B. The two groups were similar in important ways. The results showed that treatment A helped 64 out of 106 women, while comparator B helped 58 out of 111 women. However, the difference wasn\u2019t big enough to say one was definitely better than the other. Both treatments had similar times before the cancer got worse and how long the women lived. But treatment A had fewer bad side effects.\n\n**Conclusion:** In the end, treatment A was not better than comparator B for these women with advanced breast cancer.\n\nThe passage also mentions that sometimes people might try to make a study sound better than it really is by focusing on small details. But in this"
    },
    {
        "id": "34",
        "PMID": "12177098",
        "title": "Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo compare the efficacy and tolerability of treatment A with comparator B in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment.\nPatients and methods:\nIn this double\u2010blind, double\u2010dummy, parallel\u2010group study, postmenopausal patients were randomized to receive either treatment A or comparator B. The primary end point was time to progression (TTP). Secondary end points included time to treatment failure (TTF), objective response (OR) rate, duration of response (DOR), and tolerability.\nResults:\nPatients (n = 400) were followed for a median period of 16.8 months. Treatment A was not more effective than comparator B in terms of TTP (hazard ratio, 0.92; 95% confidence interval [CI], 0.74 to 1.14; P =.43); median TTP was 5.4 months with treatment A and 3.4 months with comparator B. There was no statistically significant difference between the 2 groups for TTF. Median TTF was 4.6 months for treatment A and 3.3 months for comparator B (HR, 0.96; 95% CI, 0.77 to 1.19; P = .69). At the time of this data analysis, the rate of deaths was respectively for treatment A and comparator B, 35.4% (n=73) vs. 33.5% (n=65). OR rates were 17.5% with both treatments. DOR was statistically significantly greater for treatment A compared with comparator B; the ratio of average response durations was 1.35 (95% CI, 1.10 to 1.67; P < 0.01). Both treatments were well tolerated.\nConclusion:\nTreatment A was not more effective than comparator B for postmenopausal women with advanced breast cancer whose disease progresses on tamoxifen therapy.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose of the Study:**\nThe study wanted to see if a new medicine (let's call it Treatment A) works better than an older medicine (we'll call it Comparator B) for women with advanced breast cancer who didn't get better with a previous treatment.\n\n**How They Did the Study:**\nThey had a group of women who were chosen randomly to receive either Treatment A or Comparator B. The researchers wanted to find out how long it took for the cancer to get worse again after starting the treatment and how well the women tolerated the treatments.\n\n**What They Found:**\n- They followed 400 women for about 17 months.\n- Treatment A didn\u2019t work better than Comparator B in stopping the cancer from getting worse. On average, the cancer took about 5.4 months to get worse with Treatment A and 3.4 months with Comparator B.\n- The time until the treatment stopped working was also similar for both treatments.\n- The number of women who died during the study was almost the same for both treatments.\n- Both treatments helped some women, but the time they stayed better was longer with Treatment A.\n- Both treatments were easy for the women to handle, meaning they didn\u2019t cause too many side effects.\n\n**Conclusion:**\nIn the end, Treatment A didn\u2019t work better than Comparator B for these women with advanced breast cancer who had already tried another treatment. \n\nThe study is important because it"
    },
    {
        "id": "33",
        "PMID": "12177098",
        "title": "Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo compare the efficacy and tolerability of treatment A with comparator B in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment.\nPatients and methods:\nIn this double\u2010blind, double\u2010dummy, parallel\u2010group study, postmenopausal patients were randomized to receive either treatment A or comparator B. The primary end point was time to progression (TTP). Secondary end points included objective response (OR) rate, duration of response (DOR), and tolerability.\nResults:\nPatients (n = 400) were followed for a median period of 16.8 months. Treatment A was as effective as comparator B in terms of TTP (hazard ratio, 0.92; 95% confidence interval [CI], 0.74 to 1.14; P =.43); median TTP was 5.4 months with treatment A and 3.4 months with comparator B. OR rates were 17.5% with both treatments. Clinical benefit rates (complete response + partial response + stable disease > or = 24 weeks) were 42.2% for treatment A and 36.1% for comparator B (95% CI, \u20104.00% to 16.41%; P =.26). In responding patients, median DOR (from randomization to progression) was 19.0 months for treatment A and 10.8 months for comparator B. Using all patients, DOR was significantly greater for treatment A compared with comparator B; the ratio of average response durations was 1.35 (95% CI, 1.10 to 1.67; P < 0.01). Both treatments were well tolerated.\nConclusion:\nTreatment A was at least as effective as comparator B, with efficacy end points slightly favoring treatment A. Treatment A represents an additional treatment option for postmenopausal women with advanced breast cancer whose disease progresses on tamoxifen therapy.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose of the Study:**\nThe study wanted to see if a new medicine (let's call it Treatment A) works as well as another medicine (we'll call it Comparator B) for women with advanced breast cancer who didn't get better with a previous treatment.\n\n**How They Did the Study:**\nThey had a group of women who were chosen randomly to get either Treatment A or Comparator B. The researchers didn't know which women got which treatment (this is called \"double-blind\"). They looked at how long it took for the cancer to get worse again after starting the treatment.\n\n**What They Found:**\n- They followed 400 women for about 17 months.\n- Treatment A worked just as well as Comparator B in keeping the cancer from getting worse, lasting about 5.4 months for Treatment A and 3.4 months for Comparator B.\n- Both treatments helped about the same number of women (17.5%).\n- However, women who responded to Treatment A had their cancer stay better for a longer time (about 19 months) compared to those on Comparator B (about 10.8 months).\n- Both treatments were generally safe and didn\u2019t cause too many problems.\n\n**Conclusion:**\nTreatment A is at least as good as Comparator B and might be a better option for women whose cancer got worse after using another treatment. \n\n**Important Note:**\nSometimes, studies can be tricky in"
    },
    {
        "id": "12",
        "PMID": "15947110",
        "title": "Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial",
        "journal": "Endocr Relat Cancer",
        "abstract": "This study was designed to address whether treatment A with chemotherapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2\u20104, N0\u20101, M0 breast cancer were randomized to receive either epirubicin alone (EPI) (n=105) or epirubicin plus treatment A (n=106). The primary outcome was the overall response rate. Overall, 198 patients received the planned chemotherapy dose (99 patients (94.2%) in the EPI arm and 99 patients (93.4%) in the EPI+treatment A arm). There was no statistically significant difference in overall response rate between the two treatment arms (76 versus 82% in the EPI and EPI+treatment A arms respectively). Pathological complete response was documented respectively in EPI and EPI+treatment A in 5 (4.8%) and 7 (6.7%) patients, and respectively 3 (2.9%) and 6 (5.7%) patients had carcinoma in situ. Toxicity did not differ from that expected with epirubicin. Leukopenia was the most relevant side effect, with about 50% of patients experiencing grade III\u2010IV toxicity in both arms. Platelet toxicity was uncommon and mild. Grade II\u2010III hemoglobin was observed in 15% of patients. Diarrhea and mucositis from mild to moderate occurred in 10% of patients. Acute cardiac toxicity was absent in both arms. All these side effects, attributable to epirubicin, were equally distributed in both arms. Treatment A with chemotherapy was not more effective than chemotherapy alone in breast cancer patients with operable or locally advanced disease.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nThis study looked at whether adding a new treatment (called treatment A) to a type of chemotherapy (called epirubicin) would help breast cancer patients more than just using the chemotherapy alone. The researchers worked with 211 patients who had a certain type of breast cancer that could be treated with surgery.\n\nThe patients were split into two groups: one group got only the chemotherapy, and the other group got the chemotherapy plus treatment A. They wanted to see how well each treatment worked by looking at how many patients got better.\n\nIn the end, they found that both groups had similar results. About 76% of the patients who got just chemotherapy got better, while 82% of those who got the extra treatment also got better. So, adding treatment A didn\u2019t really make a big difference.\n\nThey also looked at side effects, which are problems that can happen because of the treatment. Most patients had some side effects, like low white blood cell counts, but these were about the same for both groups. There were no serious heart problems from either treatment.\n\nOverall, the study showed that adding treatment A to chemotherapy didn\u2019t help breast cancer patients more than just using chemotherapy by itself."
    },
    {
        "id": "11",
        "PMID": "15947110",
        "title": "Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial",
        "journal": "Endocr Relat Cancer",
        "abstract": "This study was designed to address whether treatment A with chemotherapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2\u20104, N0\u20101, M0 breast cancer were randomized to receive either epirubicin alone (EPI) or epirubicin plus treatment A. Ki67 expression was evaluated immunohistochemically in tumor specimens obtained before chemotherapy by incision biopsy and at definitive surgery. Tumor shrinkage of >50% was obtained in 76% of patients randomized in the EPI arm and 81.9% of patients randomized in the EPI+treatment A arm (not significant). The corresponding rates of clinical and pathological complete response were 20.2 and 21.9% (not significant), and 4.8 and 6.7% (not significant), respectively. Pathologically complete response was more frequently observed in estrogen receptor (ER)\u2010negative (ER\u2010) tumors (P=0.04) and correlated with elevated baseline Ki67 expression (P<0.01). Both EPI treatment and EPI+treatment A resulted in a significant reduction in Ki67 expression, either in overall patients (P=0.000) or in patients with ER+ breast cancer (P=0.000). The reduction in Ki67 immunostaining in the EPI+treatment A arm was greater than in the EPI arm, leading to a lower Ki67 expression at post\u2010operative residual histology (P=0.0041). The addition of treatment A to epirubicin chemotherapy did not improve the response rate but led to a significantly higher reduction in the Ki67 expression. Baseline elevated Ki67 expression and the ER\u2010 statuses were both associated with a greater chance of obtaining a pathological complete response at residual histology.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simpler summary of the study for your fifth grader:\n\nThis study looked at how well a type of cancer treatment called chemotherapy works for women with breast cancer. The researchers wanted to see if adding another treatment (let's call it \"treatment A\") to the chemotherapy made it work better.\n\nThey studied 211 women with a certain type of breast cancer from 1997 to 2002. Some women got just the chemotherapy (called epirubicin), while others got the chemotherapy plus treatment A. They checked how much the tumors shrank after the treatment and looked at some special markers in the tumors to see how they responded.\n\nMost of the women in both groups had their tumors shrink a lot, but there wasn't a big difference between the two groups. They also looked at how many women had no signs of cancer left after treatment, and again, there wasn't a big difference between the two groups.\n\nHowever, they found that the women who had a certain type of tumor (called ER-negative) and those with higher levels of a marker called Ki67 were more likely to have no cancer left after treatment. Both groups had a decrease in Ki67, but the group that got treatment A had a bigger drop in this marker.\n\nIn the end, adding treatment A didn\u2019t really make the chemotherapy work better in terms of shrinking tumors or getting rid of cancer, but it did lower the Ki67 marker more than just chemotherapy alone.\n\nThe study also mentions that sometimes researchers might highlight certain"
    },
    {
        "id": "20",
        "PMID": "16148021",
        "title": "Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group",
        "journal": "Ann Oncol",
        "abstract": "Purpose:\nThe aim of this study was to explore the effect of dose\u2010dense sequential chemotherapy with or without treatment A primarily on disease\u2010free survival (DFS) and secondarily on overall survival (OS) in patients with high\u2010risk operable breast cancer.\nPatients and methods:\nFrom June 1997 until November 2000, 604 patients with T1\u20103N1M0 or T3N0M0 tumors were randomized to three cycles of epirubicin 110 mg/m2 followed by three cycles of treatment A followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2) (group A), or to four cycles of epirubicin followed by four cycles of CMF, as in group A (group B). All cycles were given every 2 weeks with granulocyte colony\u2010stimulating factor support.\nResults:\nA total of 595 patients were eligible. Median follow\u2010up was 61.7 months for group A and 62 months for group B. DFS and OS did not differ significantly between treatment groups (log\u2010rank P = 0.55 and P = 0.38, respectively). The 3\u2010year DFS was 80% in group A and 77% in group B. Survival rates were 93% and 90%, respectively. Comparison of quality of life outcomes between the two groups showed no statistically significant differences. Both regimens were well tolerated and severe acute side\u2010effects were infrequent. No cases of severe cardiotoxicity or acute leukemia were recorded.\nConclusion:\nTreatment A with a dose\u2010dense sequential chemotherapy was not more effective than a dose\u2010dense sequential chemotherapy alone in patients with high\u2010risk operable breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose of the Study:**\nThe study wanted to find out if a special kind of chemotherapy (a medicine to treat cancer) called \"dose-dense sequential chemotherapy\" worked better when combined with another treatment (called Treatment A) for patients with a serious type of breast cancer.\n\n**What They Did:**\nFrom June 1997 to November 2000, 604 women with a certain type of breast cancer were divided into two groups. One group got the chemotherapy with Treatment A, and the other group got just the chemotherapy without Treatment A. They received their treatments every two weeks and had support to help with side effects.\n\n**What They Found:**\nAfter following the patients for about 5 years, the researchers found that both groups had similar results. About 80% of the first group and 77% of the second group were free from cancer after 3 years. Also, most patients in both groups felt okay during the treatment, and there were very few serious side effects.\n\n**Conclusion:**\nThe study concluded that adding Treatment A didn\u2019t make the chemotherapy work any better for these patients with serious breast cancer compared to just the chemotherapy alone.\n\n**Important Note:**\nSometimes, people might try to make a study sound better than it is by focusing on small details that don\u2019t really change the main results. But in this study, the results were clear and straightforward, so we can trust what they found."
    },
    {
        "id": "19",
        "PMID": "16148021",
        "title": "Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group",
        "journal": "Ann Oncol",
        "abstract": "Purpose:\nThe aim of this study was to explore the effect of dose\u2010dense sequential chemotherapy with or without treatment A primarily on disease\u2010free survival (DFS) and secondarily on overall survival (OS) in patients with high\u2010risk operable breast cancer.\nPatients and methods:\nFrom June 1997 until November 2000, 604 patients with T1\u20103N1M0 or T3N0M0 tumors were randomized to three cycles of epirubicin 110 mg/m2 followed by three cycles of treatment A followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2) (group A), or to four cycles of epirubicin followed by four cycles of CMF, as in group A (group B). All cycles were given every 2 weeks with granulocyte colony\u2010stimulating factor support.\nResults:\nA total of 595 patients were eligible. Median follow\u2010up was 61.7 months for group A and 62 months for group B. The 3\u2010year DFS was 80% in group A and 77% in group B. Survival rates were 93% and 90%, respectively. The effect of treatment on the hazard of death was different according to hormonal receptor status. More specifically, in patients with negative receptor status the hazard of death was significantly higher for group B (hazard ratio 2.42). Both regimens were well tolerated and severe acute side\u2010effects were infrequent. No cases of severe cardiotoxicity or acute leukemia were recorded.\nConclusion:\nThe present study failed to demonstrate a significant difference in DFS or OS between the two treatment groups. However, our study has shown clearly that treatment A can be safely incorporated to dose\u2010dense sequential chemotherapy.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose of the Study:**\nThe researchers wanted to see if a special way of giving chemotherapy (a type of medicine used to treat cancer) would help people with a serious kind of breast cancer live longer without the cancer coming back.\n\n**What They Did:**\nThey looked at 604 women who had breast cancer and divided them into two groups. One group got a special treatment called \"treatment A\" along with their chemotherapy, while the other group just got the regular chemotherapy. They gave the treatments every two weeks and helped the patients with medicine to avoid getting sick from the chemotherapy.\n\n**What They Found:**\nAfter following the patients for about 5 years, they found that both groups had similar chances of not having the cancer come back and living longer. The group that got \"treatment A\" had a slightly better chance of staying cancer-free (80% compared to 77%), but the difference wasn't big enough to say one treatment was definitely better than the other. They also found that both treatments were safe, and there were no serious side effects.\n\n**Conclusion:**\nIn the end, the study didn\u2019t show a big difference between the two treatments, but it did show that \"treatment A\" can be safely used with the chemotherapy. \n\n**Important Note:**\nSometimes, when people talk about studies, they might focus on small details that sound good, even if the main results aren\u2019t very different"
    },
    {
        "id": "51",
        "PMID": "16314619",
        "title": "Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo determine whether treatment A, improves survival in patients with brain metastases when used as an adjunct to whole\u2010brain radiation therapy (WBRT).\nPatients and methods:\nPatients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assigned to receive WBRT with supplemental oxygen and either treatment A (treatment A arm) or no treatment (control arm). The primary end point was survival.\nResults:\nThe study consisted of 515 eligible patients (treatment A arm, n = 265; control arm, n = 250). The median survival time (MST) was 5.4 months for the treatment A arm versus 4.4 months for the control arm (hazard ratio [HR] = 0.87; P = .16). For the subgroup of patients with non\u2010small\u2010cell lung cancer (NSCLC) or breast cancer, the MST was 6.0 and 4.4 months, respectively (HR = 0.82; P = .07). Cox multiple regression analysis demonstrated a significant reduction in the risk of death for the treatment A arm in both primary populations. Further analysis indicated that the benefit may be restricted to the subgroup of patients with breast cancer. Response rates (radiographic complete response plus partial response) improved by 7% (P = .10) and 13% (P = .01) for all patients and for NSCLC and breast cancer patients in the treatment A arm, respectively. The most common severe adverse event in patients treated with treatment A was hypoxemia, which was reversible and effectively managed with supplemental oxygen in most patients.\nConclusion:\nThe addition of treatment A to WBRT may improve response rates and survival in patients with brain metastases, particularly metastases from breast cancer. A confirmatory trial for breast cancer patients has been initiated.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose of the Study:** The researchers wanted to find out if a new treatment (let's call it Treatment A) helps people with brain cancer live longer when they also get a type of radiation therapy called whole-brain radiation therapy (WBRT).\n\n**How They Did the Study:** They took a group of patients who had brain cancer from solid tumors and were feeling pretty good (they scored 70 or higher on a performance scale). They randomly split these patients into two groups: one group got WBRT with Treatment A, and the other group just got WBRT without Treatment A. The main thing they were looking at was how long the patients lived.\n\n**What They Found:** They studied 515 patients. The group that got Treatment A lived for an average of 5.4 months, while the group without it lived for 4.4 months. This means Treatment A might help people live a little longer, but the difference wasn't super strong. For patients with specific types of cancer (like lung or breast cancer), the results were a bit better, especially for breast cancer patients.\n\nThey also found that more patients in the Treatment A group had positive responses to the treatment, meaning their cancer got better. However, some patients had a side effect called hypoxemia (which means not getting enough oxygen), but this could usually be fixed with extra oxygen.\n\n**Conclusion:** Adding Treatment A to the radiation therapy might help some"
    },
    {
        "id": "52",
        "PMID": "16314619",
        "title": "Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo determine whether treatment A, improves survival in patients with brain metastases when used as an adjunct to whole\u2010brain radiation therapy (WBRT).\nPatients and methods:\nPatients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assigned to receive WBRT with supplemental oxygen and either treatment A (treatment A arm) or no treatment (control arm). The primary end point was survival.\nResults:\nThe study consisted of 515 eligible patients (treatment A arm, n = 265; control arm, n = 250). The median survival time (MST) was 5.4 months for the treatment A arm versus 4.4 months for the control arm (hazard ratio [HR] = 0.87; P = .16). There was no statistically significant difference between the 2 groups for response rate (complete plus partial response) (46% for the treatment A arm and 38% for the control arm; P = .10). There was not a statistically significant difference in the cumulative incidence at 1 year after random assignment of radiographic (21% treatment A vs. 18% control; p=0.53) or clinical progression (49% treatment A vs. 51% control; p = 0.49) in the brain between the treatment groups. At 6 months, respectively 16% and 15% of the patients had a stable or improving quality of life in treatment A arm and control arm. The most common severe adverse event in patients treated with treatment A was hypoxemia.\nConclusion:\nThe addition of treatment A to WBRT was not more effective than WBRT alone in patients with brain metastases.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose of the Study:**\nThe study wanted to find out if a new treatment (let's call it Treatment A) helps people with brain cancer live longer when they also get a type of radiation therapy called whole-brain radiation therapy (WBRT).\n\n**How They Did the Study:**\nThey took a group of patients who had brain cancer and were feeling okay enough to participate (they had a score of 70 or higher on a performance scale). The patients were split into two groups by chance: one group got WBRT with Treatment A, and the other group just got WBRT without Treatment A. The main thing they were looking at was how long the patients lived after the treatment.\n\n**What They Found:**\n- There were 515 patients in total: 265 got Treatment A, and 250 did not.\n- On average, the patients who got Treatment A lived for about 5.4 months, while those who didn\u2019t live for about 4.4 months.\n- However, the difference in how long they lived wasn\u2019t big enough to be sure that Treatment A really helped.\n- They also looked at how many patients got better or stayed the same, and there wasn\u2019t a big difference between the two groups.\n- At 6 months, about the same number of patients in both groups felt their quality of life was stable or getting better.\n- The only serious problem they noticed with Treatment A"
    },
    {
        "id": "37",
        "PMID": "16504757",
        "title": "A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results",
        "journal": "Int J Radiat Oncol Biol Phys",
        "abstract": "Purpose:\nTo compare treatment A and comparator B in node\u2010positive, operable breast cancer patients.\nMethods and materials:\nThis was a randomized, multicenter, phase III trial enrolling 638 eligible women with prior breast surgery and positive axillary dissection. Patients in Arm A received treatment A, with concomitant radiotherapy (50 Gy +/\u2010 10\u201020\u2010Gy boost). Patients in Arm B received comparator B, with subsequent radiotherapy.\nResults:\nMedian treatment durations were 64 and 126 days (Arms A and B, respectively), with no significant difference in overall or disease\u2010free survival. Five\u2010year locoregional relapse\u2010free survival favored patients with conservative surgery (two thirds of the population), with less local and / or regional recurrence in Arm A than in Arm B (3% vs. 9%; p = 0.01). Multivariate analysis in this subgroup showed a 2.8\u2010fold increased risk of locoregional recurrence with comparator B, independent of other prognostic factors (p = 0.027). Febrile neutropenia and Grade 3\u20104 leukopenia were significantly more frequent in Arm A. Subclinical left ventricular ejection fraction events at 1 year were more frequent with treatment A (p = 0.02).\nConclusion:\nTreatment A has significantly better locoregional control in node\u2010positive breast cancer after conservative surgery and 50% shorter treatment, albeit with slightly more acute toxicity.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\nThis study looked at two different treatments for women with a type of breast cancer that has spread to nearby areas. They wanted to see which treatment worked better. \n\nThey had 638 women in the study. Some women got Treatment A along with radiation (which is a way to kill cancer cells using high-energy rays), and others got Treatment B followed by radiation later. \n\nThe results showed that women who got Treatment A had a shorter treatment time (about 2 months) compared to those who got Treatment B (about 4 months). Both treatments worked similarly when looking at how long the women lived without the cancer coming back. However, women who had a certain type of surgery (called conservative surgery) did better with Treatment A, having fewer problems with the cancer coming back in the same area.\n\nBut there were some side effects. Women who got Treatment A had more serious side effects like low white blood cell counts and heart issues after a year. \n\nIn the end, Treatment A was better at keeping the cancer from coming back in the same area, but it also caused a few more health problems. \n\nThe passage also warns that sometimes studies can be presented in a way that makes them sound better than they really are, so we should be careful about how we understand the results."
    },
    {
        "id": "38",
        "PMID": "16504757",
        "title": "A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results",
        "journal": "Int J Radiat Oncol Biol Phys",
        "abstract": "Purpose:\nTo compare treatment A and comparator B in node\u2010positive, operable breast cancer patients.\nMethods and materials:\nThis was a randomized, multicenter, phase III trial enrolling 638 eligible women with prior breast surgery and positive axillary dissection. Patients in Arm A received treatment A, with concomitant radiotherapy (50 Gy +/\u2010 10\u201020\u2010Gy boost). Patients in Arm B received comparator B, with subsequent radiotherapy. The primary outcome was disease free survival.\nResults:\n650 women were enrolled in this trial, and a total of 638 patients were treated. Median treatment durations were 64 and 126 days (Arms A and B, respectively). Five\u2010year DFS in Arm A was 83% and in Arm B 79%, p = 0.22. Disease\u2010specific survival at 5 years was not statistically significantly different between Arm A and Arm B. Sixty\u2010eight patients died 34 in each group. There was no statistically significant difference at 5 years for regional or metastatic relapses. Local recurrences at 5 years was 3% in Arm A and 7% in Arm B, p=0.047). Febrile neutropenia (n=10 in arm A vs. n=1 in arm B) and Grade 3\u20104 leukopenia (n=43 vs n=4) were statistically significantly more frequent in Arm A. Subclinical left ventricular ejection fraction events at 1 year were more frequent with treatment A (p=0.02).\nConclusion:\nTreatment A was not more effective than comparator B in node\u2010positive, operable breast cancer patients.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose:** The study wanted to see how well two different treatments work for women with a type of breast cancer that has spread to nearby lymph nodes.\n\n**How They Did It:** They had a big test with 638 women who had already had surgery for their breast cancer. The women were split into two groups: one group got Treatment A along with radiation (which helps kill cancer cells), and the other group got Treatment B followed by radiation later. The main thing they were looking at was how long the women stayed healthy without the cancer coming back.\n\n**What They Found:** \n- They started with 650 women, but 638 actually got treated.\n- The women in the first group (Treatment A) were treated for about 64 days, while those in the second group (Treatment B) were treated for about 126 days.\n- After five years, 83% of the women in the first group were still healthy without the cancer coming back, compared to 79% in the second group. But this difference wasn\u2019t big enough to say one treatment was better than the other.\n- They also looked at how many women died from cancer, and it was about the same in both groups.\n- There were some side effects: more women in the first group had serious problems with their blood cells compared to the second group.\n- There were also some heart issues that happened more often in the first group.\n\n**Conclusion"
    },
    {
        "id": "32",
        "PMID": "17134892",
        "title": "Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group",
        "journal": "Eur J Cancer",
        "abstract": "Background:\nThe contribution of treatment A in breast cancer patients after receiving adjuvant chemotherapy is not fully established. We investigated the impact of treatment A, given sequentially after completion of adjuvant chemotherapy in patients with operable breast cancer.\nPatients and methods:\nBetween March 1991 and June 1999, 1863 women with stages I\u2010IIIA operable breast cancer who had undergone surgery and completed six cycles of adjuvant combination chemotherapy with either CMF, CAF, CEF, FAC or FEC were randomized to receive either treatment A for 3 years or no further treatment. Irrespective of menstrual status and hormone receptor content of the primary tumor, patients were stratified by institute, chemotherapy scheme and age (above 50 years or younger). The main end\u2010point was to detect a 5% increase in the 5 year survival (from 80% to 85%) in favor of treatment A. Secondary end\u2010 points were relapse free survival (RFS), local control, incidence of second primary breast cancer.\nResults:\nAfter exclusion of all patients from three sites because of inadequate documentation, a total of 1724 patients (93%) were analyzed (Treatment A 861 and Control 863). At a median follow\u2010up of 6.5 years, 396 deaths (23%) and 602 RFS events (35%) (relapse and/or death) have been observed. There was no statistically significant difference in survival between patients who were randomized to receive treatment A for 3 years and those who were randomized to no further treatment (HR 0.97; 95% CI, 0.79\u20101.18; p = 0.7377 by log\u2010rank test). At a median follow\u2010up of 6.5 years, 5\u2010year RFS on treatment A was 73% versus 67% in controls (p=0.035). Thirty eight patients (4.4%) in the treatment A arm discontinued treatment because of toxicity. The most common reasons for discontinuation were hot flashes (n = 8), vaginal bleeding (n = 7), weight gain (n = 4) and nausea (n = 4).\nConclusion:\nTreatment A in breast cancer patients after receiving adjuvant chemotherapy was not more effective than no treatment on overall survival.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nThis study looked at a new treatment (let's call it Treatment A) for women who had breast cancer and had already received some other treatments called chemotherapy. The researchers wanted to see if Treatment A would help these women live longer or stay healthy longer after their chemotherapy.\n\nThey studied 1,724 women who had surgery for their breast cancer and then finished their chemotherapy. Half of the women received Treatment A for three years, while the other half did not get any more treatment. The researchers followed these women for about 6.5 years to see what happened to them.\n\nIn the end, they found that Treatment A did not help the women live longer than those who didn\u2019t get any more treatment. However, the women who took Treatment A did have a better chance of not having their cancer come back during that time. Some women stopped taking Treatment A because it made them feel sick or caused other problems.\n\nSo, the main finding was that while Treatment A didn\u2019t help them live longer, it did help some women stay cancer-free for a while. But overall, it wasn\u2019t better than not taking any extra treatment."
    },
    {
        "id": "31",
        "PMID": "17134892",
        "title": "Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group",
        "journal": "Eur J Cancer",
        "abstract": "Background:\nThe contribution of treatment A in breast cancer patients after receiving adjuvant chemotherapy is not fully established. We investigated the impact of treatment A, given sequentially after completion of adjuvant chemotherapy in patients with operable breast cancer.\nPatients and methods:\nBetween March 1991 and June 1999, 1863 women with stages I\u2010IIIA operable breast cancer who had undergone surgery and completed six cycles of adjuvant combination chemotherapy with either CMF, CAF, CEF, FAC or FEC were randomised to receive either treatment A for 3 years or no further treatment. Irrespective of menstrual status and hormone receptor content of the primary tumour, patients were stratified by institute, chemotherapy scheme and age (above 50 years or younger). The main end\u2010point was to detect a 5% increase in the 5 year survival (from 80% to 85%) in favour of treatment A. Secondary end\u2010 points were relapse free survival (RFS), local control, incidence of second primary breast cancer and correlation of results with hormone receptor content.\nResults:\nAfter exclusion of all patients from three sites because of inadequate documentation, a total of 1724 patients (93%) were analyzed (Treatment A 861 and Control 863). At a median follow\u2010up of 6.5 years, 5\u2010year RFS on treatment A was 73% versus 67% in controls (p=0.035). No difference was seen in overall survival. The benefit of treatment A was mainly seen in the subgroup of patients with histologically documented positive axillary nodes (5\u2010year RFS on treatment A 71% versus 64% in the control group, p=0.044) and in patients with tumours expressing the ER and PR positive phenotype (5\u2010year RFS on treatment A 77% versus 70% in the control group, p=0.014).\nConclusion:\nTreatment A administered for 3 years after completion of adjuvant chemotherapy in this otherwise unselected group of patients for endocrine sensitivity had a limited impact on relapse and had no detectable effect on overall survival. The beneficial effect of treatment A is mainly confined to the subgroup of patients with node\u2010positive disease and to patients with tumours expressing the ER and PR positive phenotype.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nThis study looked at a new treatment (let's call it Treatment A) for women with breast cancer who had already received some other treatments called chemotherapy. The researchers wanted to see if Treatment A would help these women live longer or stay healthy without the cancer coming back.\n\nThey studied 1,724 women who had surgery for their breast cancer and then finished their chemotherapy. Half of the women got Treatment A for three years, and the other half did not get any more treatment. They followed these women for about 6.5 years to see what happened.\n\nThe results showed that women who got Treatment A had a better chance of not having their cancer come back compared to those who didn\u2019t get it (73% vs. 67%). However, when they looked at how long the women lived overall, there was no big difference between the two groups.\n\nThe researchers found that Treatment A seemed to help more for certain groups of women, especially those with more serious cancer (called node-positive) and those whose cancer had specific characteristics (called ER and PR positive).\n\nIn the end, while Treatment A helped some women not have their cancer come back, it didn\u2019t help them live longer overall. So, the researchers think we should be careful about how much we say this treatment is helpful, especially since it didn\u2019t work for everyone."
    },
    {
        "id": "1",
        "PMID": "17173959",
        "title": "Effective cervical neoplasia detection with a novel optical detection system: a randomized trial",
        "journal": "Gynecol Oncol",
        "abstract": "Objective:\nTo assess whether the use of intervention A as an adjunct to colposcopy increases the detection of biopsy confirmed CIN 2, 3 (high grade cervical intraepithelial neoplasia).\nMethods:\nThis is a multicenter two\u2010arm randomized trial comparing colposcopy alone with colposcopy plus intervention A. Patients were recruited from 13 colposcopy clinics in a variety of practice settings. 2299 women referred for the evaluation of an abnormal cervical cytology were randomized with stratification by cytology; subsequently 113 women were excluded for a variety of reasons. The main study outcomes were differences in true\u2010positive rates (CIN 2, 3 and cancer identified) and false\u2010positive rates between the study arms.\nResults:\nThe true\u2010positive (TP) rates were 14.4% vs. 11.4% (p=0.035, one\u2010sided) for the combined colposcopy and intervention A arm compared to colposcopy\u2010only arm, respectively, in women with either an atypical squamous cell (ASC) or low\u2010grade squamous intraepithelial lesion (LSIL) cytology result. TP rates were similar between the two arms among women referred for the evaluation of HSIL (high\u2010grade squamous intraepithelial lesion). The 26.5% gain in true\u2010positives observed with the use of intervention A and colposcopy among women referred for an ASC or LSIL cytology was achieved with only a fractional increase in number of biopsies obtained per patient (0.30) and a modest increase in false\u2010positive rate\n(4%). In the combined colposcopy and intervention A arm among women with ASC or LSIL, the PPV (positive predictive value) of biopsies indicated by ntervention A was 15.0% and the PPV of biopsies indicated by colposcopy was 15.2%. Joint hypothesis testing indicates that intervention A and colposcopy provides benefit compared to colposcopy alone among women with ASC or LSIL.\nConclusion:\nCombining intervention A with colposcopy provides a clinically meaningful increase in the detection of CIN 2, 3 in women referred for the evaluation of mildly abnormal cytology results.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**What the Study Was About:**\nThe study wanted to find out if adding a special treatment (let's call it \"intervention A\") to a medical procedure called colposcopy would help doctors find more cases of a serious condition called CIN 2 or CIN 3 in women who had abnormal test results.\n\n**How They Did the Study:**\nThey did the study in 13 different clinics and had almost 2,300 women take part. Some women only had the colposcopy, while others had both the colposcopy and the special treatment. They looked at how many true cases of CIN 2 or CIN 3 were found and how many times they thought there was a problem when there really wasn\u2019t (that\u2019s called a false positive).\n\n**What They Found:**\nThe results showed that using the special treatment along with colposcopy helped find more true cases of CIN 2 or CIN 3 in women with certain types of abnormal test results. They found 14.4% of true cases with the special treatment compared to 11.4% without it. This means that the special treatment helped find more problems, but it also meant they had a few more false alarms (4% more).\n\n**Conclusion:**\nIn the end, the study suggested that using the special treatment with colposcopy is a good idea because it helps doctors find more serious problems in women who have slightly abnormal test"
    },
    {
        "id": "2",
        "PMID": "17173959",
        "title": "Effective cervical neoplasia detection with a novel optical detection system: a randomized trial",
        "journal": "Gynecol Oncol",
        "abstract": "Objective:\nTo assess whether the use of intervention A as an adjunct to colposcopy increases the detection of biopsy confirmed CIN 2,3 (high grade cervical intraepithelial neoplasia).\nMethods:\nThis is a multicenter two\u2010arm randomized trial comparing colposcopy alone with colposcopy plus intervention A. Patients were recruited from 13 colposcopy clinics in a variety of practice settings. 2299 women referred for the evaluation of an abnormal cervical cytology were randomized with stratification by cytology; subsequently 113 women were excluded for a variety of reasons. The main study outcomes were differences in true\u2010positive rates (biopsy confirmed CIN 2, 3 and cancer) and false\u2010positive rates (all women having at least one cervical biopsy taken with none of the biopies diagnosed as CIN 2,3, or cancer) between the study arms.\nResults:\nThe final analyzed populations were 1096 in the colposcopy only arm and 1090 in the colposcopy plus intervention A arm. There was no statistically significant difference in the true positive rate between the 2 groups. The true positive rate was 19.9% (218/1096) in the colposcopy\u2010only arm vs 21.8% (238/1090) in the colposcopy plus intervention A arm; p=0.143. The false positive rate was 57.4% (629/1096) in the colposcopy\u2010only arm vs 60.5% (659/1090) in the colposcopy plus intervention A arm. No biopsy was performed in 239 (27.4%) in the colposcopy\u2010only arm and 193 (17.7%) in the colposcopy plus intervention A arm. The average number of biopsies was 1.03 for the colposcopy\u2010only arm and 1.30 for the colposcopy plus intervention A arm. Four subjects experienced minor adverse events during the study in both arms.\nConclusion:\nCombining intervention A with colposcopy was not more effective than colposcopy alone for the detection of CIN 2, 3 in women referred for the evaluation of mildly abnormal cytology results.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**What the Study Was About:**\nThe researchers wanted to find out if adding a special treatment (called intervention A) to a procedure called colposcopy would help doctors find more cases of a serious condition called CIN 2 or CIN 3 in women who had abnormal test results.\n\n**How They Did the Study:**\nThey did a big experiment with 2,299 women who were sent to the doctor because their tests showed something unusual. The women were split into two groups: one group only had the colposcopy, and the other group had the colposcopy plus the special treatment. They looked at how many women in each group actually had the serious condition after getting a biopsy (a test where a small piece of tissue is taken out to check for problems).\n\n**What They Found:**\nAfter looking at the results, they found that the group that had the special treatment didn\u2019t find more cases of CIN 2 or CIN 3 than the group that just had the colposcopy. In fact, about 20% of the women in the colposcopy-only group had the serious condition, while about 22% in the other group did. But the difference wasn\u2019t big enough to say that the special treatment really helped.\n\nThey also noticed that more women in the group with the special treatment had biopsies done, but there were no major problems from the procedures.\n\n**Conclusion:**\nIn the end"
    },
    {
        "id": "39",
        "PMID": "17179098",
        "title": "Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo evaluate the efficacy and tolerability of treatment A plus cyclophosphamide, doxorubicin, and fluorouracil (CAF) therapy in comparison with CAF alone, in patients with advanced or recurrent breast cancer.\nMethods and materials:\nIn this randomized, double\u2010blind, placebo\u2010controlled trial, patients were treated with six cycles of CAF therapy: 28 days/cycle, with doxorubicin (25 mg/m2) and fluorouracil (500 mg/m2) administered on days 1 and 8 and cyclophosphamide (100 mg orally [PO]) administered on day 1 through 14. Primary end point was overall response rate (ORR; partial or complete response). In total, 221 patients were assessable.\nResults:\nORR was 42.6% for CAF compared with 53.1% for treatment A + CAF, a 24.6% relative improvement and 10.5% absolute increase (P = .077). There was a trend for prolonged progression\u2010free survival (PFS; median 241 days for CAF v 366 days for treatment A + CAF; P = .145). In retrospectively defined subgroups, significant improvement in PFS in favor of treatment A was observed in patients who were premenopausal, had no prior therapy, and were stage IV at diagnosis with an intact primary tumor. Except for neutropenia and leukopenia, there was no statistically significant excess of grade 3/4 adverse events compared with CAF. Treatment with treatment A did not affect the plasma concentration of doxorubicin.\nConclusion:\nTreatment A + CAF was well tolerated and is suggested to have efficacy in patients who had not received prior therapy.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose:** The study wanted to see if a new treatment (let's call it Treatment A) combined with a standard cancer treatment (called CAF) works better than just using CAF alone for people with advanced breast cancer.\n\n**How They Did It:** They had a group of patients and divided them into two. One group got Treatment A with CAF, and the other group just got CAF. They gave the treatments for six cycles, which means they treated the patients for about six months. They looked to see how many patients got better after the treatment.\n\n**Results:** They found that 53 out of 100 patients who got Treatment A with CAF got better, while 43 out of 100 patients who only got CAF got better. This means Treatment A seemed to help a bit more. They also noticed that some patients who were younger and hadn\u2019t had treatment before did even better with Treatment A. Most patients didn\u2019t have serious side effects, but a few had low blood cell counts.\n\n**Conclusion:** The study suggests that Treatment A combined with CAF is safe and might help patients who haven\u2019t had treatment before.\n\n**Important Note:** Sometimes, studies can make results sound better than they really are, especially if they focus on certain groups of patients or other details. So, we should be careful and think critically about what the study is saying."
    },
    {
        "id": "40",
        "PMID": "17179098",
        "title": "Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo evaluate the efficacy and tolerability of treatment A plus cyclophosphamide, doxorubicin, and fluorouracil (CAF) therapy in comparison with CAF + placebo, in patients with advanced or recurrent breast cancer.\nMethods and materials:\nIn this randomized, double\u2010blind, placebo\u2010controlled trial, patients were treated with six cycles of CAF therapy: 28 days/cycle, with doxorubicin (25 mg/m2) and fluorouracil (500 mg/m2) administered on days 1 and 8 and cyclophosphamide (100 mg orally [PO]) administered on day 1 through 14. Primary end point was overall response rate (ORR; partial or complete response). In total, 221 patients were assessable.\nResults:\nA total of 227 patients were recruited, the full analysis set consisted of 221 patients. ORR was 42.6% (95% confidence interval (CI), 33.1 to 52.5) for CAF + placebo compared with 53.1% (95% CI, 43.5 to 62.5) for treatment A + CAF (P = .077). The median progression\u2010free survival (PFS) was 241 days for CAF + placebo v 366 days for treatment A + CAF; P = .145. Any adverse event occurred more frequently with CAF + treatment A, 95.5% vs. 88.4%, p=0.025. Neutropenia occurred for 91.2% with CAF + treatment A vs 77.7% with CAF + placebo, p=0.005. Treatment with treatment A did not affect the plasma concentration of doxorubicin.\nConclusion:\nTreatment A + CAF was not more effective than CAF + placebo in patients with advanced or recurrent breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose:** The study wanted to see if a new treatment (let's call it Treatment A) works better than just using a regular treatment (CAF) with a fake medicine (placebo) for people who have advanced breast cancer.\n\n**How They Did It:** They had a group of patients and gave some of them Treatment A along with CAF, while others just got CAF with the fake medicine. They looked at how well the treatments worked over six cycles, which means they treated the patients for about six months.\n\n**What They Found:** Out of 227 patients, they could really look at the results for 221 of them. They found that 53% of the patients who got Treatment A and CAF showed improvement, while 43% of those who got just CAF with the fake medicine showed improvement. However, the difference wasn\u2019t big enough to say that Treatment A was definitely better. \n\nThey also looked at how long the patients stayed healthy without the cancer getting worse. Those who got Treatment A stayed healthy for about 366 days, while those who got just CAF stayed healthy for about 241 days. Again, the difference wasn\u2019t big enough to say Treatment A was better.\n\n**Side Effects:** More people who got Treatment A had side effects compared to those who just got CAF with the fake medicine. For example, a lot more people had a problem called neutropenia, which means their white blood cells were"
    },
    {
        "id": "53",
        "PMID": "17264336",
        "title": "Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nIn 1996, we initiated the multicenter phase III randomized trial to compare the effect on disease\u2010free survival (DFS) of experimental treatment A versus comparator B after breast\u2010conserving surgery for stages I and II breast cancer. This report presents the clinical results with a median follow\u2010up of 60 months.\nPatients and methods:\nBetween February 1996 and April 2000, 716 patients were entered onto this trial. Adjuvant treatment began within 6 weeks after surgery.\nResults:\nThere was no statistically significant difference in treatment in the 5\u2010year DFS (80% in both groups; P = .83), locoregional recurrence\u2010free survival (LRFS; 92% in comparator B v 95% in treatment A; P = .76), metastasis\u2010free survival (87% in comparator B v 84% in treatment A; P = .55), or overall survival (90% in comparator B v 91% in treatment A; P = .76). Nevertheless, in the node\u2010positive subgroup, the 5\u2010year LRFS was statistically better in the treatment A arm (97% in treatment A v 91% in comparator B; P = .02), corresponding to a risk of locoregional recurrence decreased by 39% (hazard ratio, 0.61; 95% CI, 0.38 to 0.93).\nConclusion:\nThis treatment protocol remains an appealing clinical option for many women with operable breast cancer at a high risk of recurrence. Combination treatments with new drugs for breast cancer are warranted.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n---\n\n**What the Study Was About:**\nIn 1996, doctors started a big study to see if a new treatment (let's call it Treatment A) was better than an old treatment (Treatment B) for women who had early-stage breast cancer and had surgery to remove the tumor. They wanted to find out how long the women could stay healthy after their treatment.\n\n**What They Did:**\nFrom 1996 to 2000, 716 women joined the study. They started their treatments about 6 weeks after their surgery.\n\n**What They Found:**\nAfter 5 years, both groups of women (those who got Treatment A and those who got Treatment B) had similar chances of staying healthy. For example, 80% of women in both groups were still healthy after 5 years. They also looked at other things like how many women had their cancer come back in the same area or spread to other places, and the results were also similar.\n\nHowever, there was a special group of women who had a certain type of cancer that was more serious (called node-positive). In this group, those who got Treatment A did better at not having their cancer come back in the same area compared to those who got Treatment B.\n\n**What It Means:**\nThe study suggests that Treatment A might be a good option for some women with breast cancer, especially those at higher risk of their cancer coming back."
    },
    {
        "id": "54",
        "PMID": "17264336",
        "title": "Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nIn 1996, we initiated the multicenter phase III randomized trial to compare the effect on disease\u2010free survival (DFS) of experimental treatment A versus comparator B after breast\u2010conserving surgery for stages I and II breast cancer. This report presents the clinical results with a median follow\u2010up of 60 months.\nPatients and methods:\nBetween February 1996 and April 2000, 716 patients were entered onto this trial (358 randomized to comparator B and 358 to treatment A) and respectively 343 and 352 patients were included in the analysis. Adjuvant treatment began within 6 weeks after surgery. The primary endpoint was disease\u2010free survival (DFS) defined as the time from randomization to the first treatment failure (in the ipsilateral breast, in the axillary/infraclavicular/IMCs, or at a distant site) or death (if no recurrence had been noted).\nResults:\nThere was no statistically significant difference in treatment in the 5\u2010year DFS (80% in both groups; P = .83), locoregional recurrence\u2010free survival (LRFS; 92% in comparator B v 95% in treatment A; P = .76), metastasis\u2010free survival (87% in comparator B v 84% in treatment A; P = .55), or overall survival (90% in comparator B v 91% in treatment A; P = .76).\nConclusion:\nTreatment A was not more effective than comparator B after breast\u2010conserving surgery for stages I and II breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose:** In 1996, doctors started a big study to see if a new treatment (let's call it Treatment A) was better than an old treatment (we'll call it Treatment B) for women who had surgery for early-stage breast cancer. They wanted to find out how long people could stay healthy after their treatment.\n\n**Patients and Methods:** From 1996 to 2000, 716 women joined the study. Half of them got Treatment A, and the other half got Treatment B. The doctors checked how well each treatment worked about 5 years after the surgery.\n\n**Results:** After 5 years, both groups of women had similar results. About 80% of women in both groups were still healthy. There were also no big differences in other important health measures between the two treatments.\n\n**Conclusion:** The new treatment (Treatment A) didn\u2019t work better than the old treatment (Treatment B) for these women after their surgery.\n\nThe passage also mentions that sometimes people might try to make a study sound better than it really is by focusing on small details. But in this case, the study results were clear and straightforward, so we can trust what they found."
    },
    {
        "id": "4",
        "PMID": "17530429",
        "title": "Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis",
        "journal": "Breast Cancer Res Treat",
        "abstract": "The randomized multicenter study on rapidly proliferating breast cancer was activated at the end of the 1980s. The present work investigated whether and to what degree the short\u2010term advantages observed from treatment A were maintained at a longer follow\u2010up. Two hundred and eighty\u2010one patients with node\u2010negative and high TLI tumors were randomized to receive treatment A or no further treatment. Overall, at a median follow\u2010up of 12 years, 99 relapses have been observed, 55 in the control arm and 44 in the treatment A arm. At a median follow\u2010up of 12 years, there was no statistically significant difference between treatment A and no treatment for the cumulative incidence of relapse, Hazard Ratio (HR) [95% confidence interval] = 0.75 [0.50\u20101.13]; p= 0.17 and for the cumulative incidence of death HR = 0.80 [0.48\u20101.33], p= 0.38. The incidence of contralateral tumors was similar in the two arms (10 vs. 11). Treatment A was not more effective than no treatment on rapidly proliferating breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\nA long time ago, scientists started a study to see if a certain treatment (let's call it Treatment A) could help people with a type of breast cancer that grows quickly. They wanted to find out if this treatment worked better than not getting any treatment at all.\n\nIn the study, they looked at 281 patients who had a specific kind of cancer that wasn't spreading to their lymph nodes. Some of these patients got Treatment A, while others did not get any treatment. They followed these patients for about 12 years to see what happened.\n\nAfter 12 years, they found that 99 patients had their cancer come back. Out of those, 55 were in the group that didn't get Treatment A, and 44 were in the group that did. They also looked at how many people died from cancer and found no big difference between the two groups.\n\nIn the end, the study showed that Treatment A didn't work any better than not getting treatment for this type of breast cancer. So, the scientists concluded that Treatment A wasn't more helpful than doing nothing. \n\nThe passage also mentions that sometimes people can twist the results of studies to make them sound better than they really are, but this study was clear and didn't do that."
    },
    {
        "id": "3",
        "PMID": "17530429",
        "title": "Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis",
        "journal": "Breast Cancer Res Treat",
        "abstract": "The randomized multicenter study on rapidly proliferating breast cancer was activated at the end of the 1980s. The present work investigated whether and to what degree the short\u2010term advantages observed from treatment A were maintained at a longer follow\u2010up. Two hundred and eighty\u2010one patients with node\u2010negative and high TLI tumors were randomized to receive treatment A or no further treatment. At a median follow\u2010up of 12 years, treatment A produced a 25% and 20% relative reduction in relapse and death cumulative incidence, respectively. A breakdown analysis identified a subgroup of patients with intermediate proliferating tumors for whom a 70% and 73% reduction in relapse and death was observed in the intention\u2010to\u2010treat population. An even higher reduction of 80% and 84% in relapse and death was seen for the patients who had received the full treatment A dose. We identified a subgroup of patients with intermediate proliferating tumors in whom the high benefit obtained from treatment A was maintained at a long\u2010term follow up.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simpler summary for your fifth grader:\n\nA long time ago, scientists started a study to see how well a certain treatment (let's call it Treatment A) works for people with a type of breast cancer that grows quickly. They wanted to find out if the good results from Treatment A would last over time.\n\nIn the study, they looked at 281 patients who didn't have cancer spread to their lymph nodes. Some of these patients got Treatment A, while others didn\u2019t get any more treatment. After about 12 years, they found that Treatment A helped a lot. It reduced the chances of the cancer coming back by 25% and the chances of dying from it by 20%.\n\nThey also noticed that there was a special group of patients with a certain type of tumor that did even better. For these patients, Treatment A reduced the chances of cancer coming back by 70% and the chances of dying by 73%. If they got the full dose of Treatment A, the results were even better\u201480% less chance of relapse and 84% less chance of dying.\n\nHowever, the scientists warned that sometimes studies can be tricky. They might highlight only the good parts or focus on certain groups to make the treatment look better than it really is. So, when reading about studies like this, it\u2019s important to be careful and think critically about the results."
    },
    {
        "id": "36",
        "PMID": "18794551",
        "title": "Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III randomized open\u2010label clinical trial was designed to evaluate the efficacy and safety of treatment A versus comparator B as first\u2010line treatment for metastatic breast cancer (MBC) in postmenopausal women.\nPatients and methods:\nThe study was conducted at 81 centers and enrolled postmenopausal patients with measurable hormone\u2010sensitive metastatic or locally advanced breast cancer. Prior adjuvant chemotherapy and/or comparator B were allowed. One previous chemotherapy regimen and no prior hormone therapy for advanced disease were permitted. Patients were randomly assigned to receive treatment A or comparator B until disease progression or unacceptable toxicity occurred. Progression\u2010free survival (PFS) as the primary study end point.\nResults:\nOf the 382 patients randomized at 79 sites, 371 (182 treatment A, 189 comparator B) were included in the analysis. No treatment related death were observed. A total of 319 events (progression or death) were observed: 161 (85%) in the comparator B arm and 158 (87%) in the treatment A arm. Median progression\u2010 free survival (PFS) (primary outcome) was 5.8 months with comparator B (95% CI, 5.3 to 8.1 months) vs 9.9 months; (95% CI, 8.7 to 11.8 months) with treatment A, HR = 0.84 (95% CI, 0.67 to 1.05), p = .121. No statistically significant differences in overall survival were observed between treatment arms: median overall survival for comparator B and treatment A was 43.3 vs. 37.2 months, HR=1.04 (95% CI, 0.76 to 1.41). Overall response rate was respectively for treatment A and for comparator B, 46% vs. 31%; odds ratio=1.85; 95% CI, 1.21 to 2.82; P = .005.\nConclusion:\nTreatment A was not more effective than comparator B for metastatic breast cancer in postmenopausal women on overall survival.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose of the Study:**\nThe researchers wanted to see if a new medicine (let's call it Treatment A) works better and is safer than an older medicine (we'll call it Comparator B) for women who have a type of breast cancer that has spread to other parts of the body.\n\n**How They Did the Study:**\nThey did the study in 81 different places and included women who had a certain kind of breast cancer. Some of these women had already received other treatments before. The women were randomly put into two groups: one group got Treatment A, and the other group got Comparator B. They kept giving the treatments until the cancer got worse or the women had bad side effects.\n\n**What They Found:**\nOut of 382 women in the study, they looked closely at 371 of them. They found that both treatments had some problems, but no one died because of the treatments. They checked how long the women lived without their cancer getting worse. The women who took Treatment A lived without their cancer getting worse for about 9.9 months, while those who took Comparator B lived without it getting worse for about 5.8 months. \n\nHowever, when they looked at how long the women lived overall, there wasn\u2019t a big difference between the two treatments. The women on Comparator B lived for about 43.3 months, while those on Treatment A lived for about 37."
    },
    {
        "id": "35",
        "PMID": "18794551",
        "title": "Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III randomized open\u2010label clinical trial was designed to evaluate the efficacy and safety of treatment A versus comparator B as first\u2010line treatment for metastatic breast cancer (MBC) in postmenopausal women.\nPatients and methods:\nThe study was conducted at 81 centers and enrolled postmenopausal patients with measurable hormone\u2010sensitive metastatic or locally advanced breast cancer. Prior adjuvant chemotherapy and/or comparator B were allowed. One previous chemotherapy regimen and no prior hormone therapy for advanced disease were permitted. Patients were randomly assigned to receive treatment A or comparator B until disease progression or unacceptable toxicity occurred.\nResults:\nA total of 371 patients enrolled at 79 sites (182 treatment A, 189 comparator B) were included in the analysis. Both treatments were generally well tolerated without major toxicity. Overall response rate was greater for treatment A than for comparator B (46% v 31%; odds ratio = 1.85; 95% CI, 1.21 to 2.82; P = .005). Median progression\u2010free survival (PFS) was longer with treatment A (9.9 months; 95% CI, 8.7 to 11.8 months) than with comparator B (5.8 months; 95% CI, 5.3 to 8.1 months). However, these early differences (Wilcoxon P = .028) did not translate to a longer\u2010term benefit in PFS, the primary study end point (log\u2010rank P = .121). There was also no difference in survival between both study arms.\nConclusion:\nTreatment A is an effective and well\u2010tolerated first\u2010line hormonal treatment for postmenopausal women with MBC and offers significant early improvement in time to tumor progression when compared with comparator B.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\nThis study looked at two different treatments for women who have a type of breast cancer that has spread. The researchers wanted to see which treatment worked better and was safer. They had 371 women in the study, and they randomly gave some of them Treatment A and others Treatment B.\n\nThe results showed that more women who got Treatment A had their cancer shrink or get better compared to those who got Treatment B. Also, women on Treatment A were able to go longer without their cancer getting worse\u2014about 10 months compared to almost 6 months for Treatment B. \n\nHowever, even though Treatment A seemed better at first, in the long run, both treatments worked about the same when it came to how long the women lived. \n\nIn the end, the researchers said that Treatment A is a good option for these women because it helps them feel better for a while. But they also warned that sometimes studies can make things sound better than they really are, so we should be careful about how we understand the results."
    },
    {
        "id": "17",
        "PMID": "18955454",
        "title": "Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTreatment A is effective against HER\u20102\u2010positive locally advanced or metastatic breast cancer (MBC). This phase III trial evaluated the efficacy of treatment A in HER\u20102\u2010negative and HER\u20102\u2010uncharacterized MBC.\nPatients and methods:\nWomen with MBC were randomly assigned to first\u2010line therapy with paclitaxel 175 mg/m2 every 3 weeks plus treatment A or placebo. A preplanned retrospective evaluation of HER\u20102 status was performed using fluorescence in situ hybridization and immunohistochemistry. The primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), clinical benefit rate (CBR), event\u2010free survival (EFS), and overall survival (OS).\nResults:\nIn the intent\u2010to\u2010treat population (n = 579), there were no significant differences in TTP, EFS, or OS between treatment arms, although differences in ORR and CBR were noted. In 86 HER\u20102\u2010positive patients (15%), treatment with paclitaxel\u2010 treatment A resulted in statistically significant improvements in TTP, EFS, ORR, and CBR compared with paclitaxel\u2010placebo. No differences between treatment groups were observed for any end point in HER\u20102\u2010negative patients. The most common adverse events were alopecia, rash, and diarrhea. The incidence of diarrhea and rash was significantly higher in the paclitaxel\u2010treatment A arm. The rate of cardiac events was low, and no difference was observed between treatment arms.\nConclusion:\nPatients with HER\u20102\u2010negative or HER\u20102\u2010untested MBC did not benefit from the addition of treatment A to paclitaxel. However, first\u2010line therapy with paclitaxel\u2010 treatment A significantly improved clinical outcomes in HER\u20102\u2010positive patients. Prospective evaluation of the efficacy and safety of this combination is ongoing in early and metastatic HER\u20102\u2010positive breast cancer patients.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\nThis study looked at a new medicine called Treatment A to see if it helps women with a type of breast cancer called HER-2-positive cancer. They compared it to a fake medicine (placebo) to see which one worked better.\n\nThey gave some women Treatment A along with another medicine called paclitaxel, while other women got paclitaxel with the fake medicine. They wanted to find out how long the women could stay healthy without the cancer getting worse and how many women got better.\n\nIn the end, they found that for women with HER-2-positive cancer, Treatment A helped them do better and stay healthier longer. But for women with HER-2-negative cancer (which is a different type), Treatment A didn\u2019t help at all.\n\nThey also noticed some side effects, like hair loss and skin rashes, which were more common in the group that got Treatment A. Overall, they learned that Treatment A is good for some women with breast cancer, but not for everyone.\n\nThe study also mentioned that sometimes people might make the results sound better than they really are, so we should be careful when reading about studies like this."
    },
    {
        "id": "18",
        "PMID": "18955454",
        "title": "Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III trial evaluated the efficacy of treatment A in locally advanced or metastatic breast cancer (MBC).\nPatients and methods:\nWomen with MBC were randomly assigned to first\u2010line therapy with paclitaxel 175 mg/m2 every 3 weeks plus treatment A or placebo. The primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), clinical benefit rate (CBR), event\u2010free survival (EFS), and overall survival (OS).\nResults:\nThis trial enrolled 580 patients. In the intent\u2010to\u2010treat population (n = 579), there were no statistical significant differences between treatment A+paclitaxel and placebo+paclitaxel in TTP (29 v 22.9 weeks, HR = 0.87; 95% CI, 0.72 to 1.05; p = .142), EFS (25.1 vs. 22.6 weeks, HR = 0.90 [0.75\u20101.08], p = 0.238), or OS (99.1 vs. 87 weeks, HR = 0.86 [0.7\u20101.1], p = 0.216). The ORR and CBR were respectively for treatment A and placebo 35.1% vs. 25.3%, p = 0.008 and 40.5% vs. 31.9%, p = 0.025. The most common adverse events were alopecia, rash, and diarrhea. The incidence of diarrhea, rash, mucositis, and vomiting was significantly higher in the paclitaxel\u2010treatment A arm. The rate of cardiac events was low, and no statistical difference was observed between treatment arms. AEs led to treatment discontinuation in 48 patients (16%) in the paclitaxel\u2010treatment A arm compared with 20 patients (7%) in the paclitaxel\u2010placebo arm.\nConclusion:\nTreatment A plus paclitaxel was not more effective than paclitaxel alone on overall survival for patients with locally advanced or metastatic breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n---\n\n**Purpose of the Study:**\nThe study looked at how well a new treatment (called Treatment A) works for women with a serious type of breast cancer that has spread or is hard to treat.\n\n**What They Did:**\nThey took a group of women with this type of breast cancer and randomly divided them into two groups. One group got Treatment A along with a medicine called paclitaxel, and the other group got paclitaxel with a fake treatment (placebo). They wanted to see how long the women could go without their cancer getting worse and how well the treatments worked overall.\n\n**Results:**\nThey included 580 women in the study. They found that there wasn\u2019t a big difference in how long the cancer stayed under control or how long the women lived between the two groups. However, the group that got Treatment A had a better response rate (more women saw their cancer shrink) and a better clinical benefit rate (more women felt their treatment was helping them) compared to the group that got the fake treatment.\n\nSome women had side effects like hair loss, rashes, and diarrhea, and these were more common in the group that got Treatment A. A few women had to stop their treatment because of these side effects.\n\n**Conclusion:**\nIn the end, Treatment A didn\u2019t help women live longer compared to just using paclitaxel alone, even though it did help some women"
    },
    {
        "id": "15",
        "PMID": "19273714",
        "title": "Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III study compared the efficacy and safety of treatment A with comparator B in advanced breast cancer.\nPatients and methods:\nPatients were randomly assigned to treatment A or comparator B. Comparison of progression\u2010free survival (PFS) was the primary objective.\nResults:\nPatient characteristics were balanced between arms (N = 305). Median PFS was 8.05 months (95% CI, 6.60 to 8.71) for treatment A and 7.98 (95% CI, 6.93 to 8.77) for comparator B (log\u2010rank P = .121). Overall response rate (ORR) was 32% in both arms, and overall survival (OS) was not different between arms (P = .983). Time to treatment failure (TTF; defined as discontinuation, progressive disease, death as a result of any cause, or the start of a new anticancer therapy) was superior in the treatment A arm (P = .059). Hematologic toxicity was similar in both arms, except for grades 3 to 4 leukopenia (treatment A, 78%; comparator B, 66%; P = .025) and transfusions (treatment A, 17%; comparator B, 7%; P = .0051). Grades 3 to 4 diarrhea, mucositis, and hand\u2010and\u2010foot syndrome were significantly higher in the comparator B arm. Fewer patients in the treatment A arm discontinued because of drug\u2010related adverse events (13% v 27% in CD; P = .002).\nConclusion:\nNo difference was observed between treatment A and comparator B arms in PFS, ORR, and OS. TTF was longer in the treatment A arm. These findings, combined with a nonhematologic toxicity profile that favors treatment A over approved doses of comparator B, suggest that treatment A may be a better option than comparator B in this clinical setting.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose of the Study:** The researchers wanted to see if a new medicine (let's call it Treatment A) works better and is safer than another medicine (we'll call it Comparator B) for people with advanced breast cancer.\n\n**How They Did the Study:** They took a group of patients and randomly gave them either Treatment A or Comparator B. They mainly wanted to find out how long patients could live without their cancer getting worse.\n\n**What They Found:** \n- There were 305 patients in the study, and both groups were similar in terms of their health.\n- Patients taking Treatment A lived without their cancer getting worse for about 8.05 months, while those on Comparator B lived for about 7.98 months. This difference wasn\u2019t very big, so it\u2019s hard to say one is better than the other.\n- Both treatments helped about 32% of patients, which means the same number of people responded well to both treatments.\n- The time it took for patients to stop treatment because of problems was longer for those on Treatment A.\n- Some side effects (like low blood cell counts) were more common with Treatment A, but other side effects (like diarrhea and skin problems) were worse with Comparator B.\n- Fewer people stopped taking Treatment A because of side effects compared to those on Comparator B.\n\n**Conclusion:** Overall, the study didn\u2019t find a big difference between the two treatments in how"
    },
    {
        "id": "16",
        "PMID": "19273714",
        "title": "Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III study compared the efficacy and safety of treatment A with comparator B in advanced breast cancer.\nPatients and methods:\nPatients were randomly assigned to treatment A or comparator B. Comparison of progression\u2010free survival (PFS) was the primary objective.\nResults:\nPatient characteristics were balanced between arms (N = 305). Median PFS was 8.05 months (95% CI, 6.60 to 8.71) for treatment A and 7.98 (95% CI, 6.93 to 8.77) for comparator B (log\u2010rank P = .121). Overall response rate (ORR) was 32% in both arms, p=0.931. The median time to treatment failure (TTF; defined as discontinuation, progressive disease, death as a result of any cause, or the start of a new anticancer therapy) was 4.24 months (95% CI, 4.11 to 4.44) for treatment A and 4.07 months (95% CI, 3.81 to 4.24) for comparator B, p=0.059. The medial overall survival was 19.29 months (95% CI, 15.57 to 23.59) for treatment A vs. 21.45 months (95% CI, 17.12 to 24.94), p=0.983. Hematologic toxicity was similar in both arms, except for grades 3 to 4 leukopenia (treatment A, 78%; comparator B, 66%; P = .025) and transfusions (treatment A, 17%; comparator B, 7%; P = .0051) and grades 3 to 4 diarrhea (treatment A, 8%; comparator B, 18%; p=0.009), mucositis (treatment A, 4%; comparator B, 15%; p<.001), and hand\u2010and\u2010foot syndrome (treatment A, 0%; comparator B, 26%, p<.001). 13% in treatment A arm and 27% in the comparator B arm discontinued because of drug\u2010related adverse events (P = .002).\nConclusion:\nTreatment A was not more effective than comparator B for patients with advanced breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose of the Study:**\nThe study wanted to see if a new medicine (let's call it Treatment A) works better and is safer than another medicine (we'll call it Comparator B) for people with advanced breast cancer.\n\n**How They Did the Study:**\nThey took a group of patients and randomly divided them into two groups. One group got Treatment A, and the other group got Comparator B. They mainly looked at how long patients could live without their cancer getting worse.\n\n**What They Found:**\n- There were 305 patients in total, and both groups were similar in terms of their health.\n- Patients taking Treatment A lived without their cancer getting worse for about 8.05 months, while those on Comparator B lived for about 7.98 months. This difference wasn\u2019t very big.\n- Both groups had the same overall response to the treatment, with 32% of patients showing improvement.\n- The time until patients had to stop treatment or their cancer got worse was about the same for both groups.\n- The average time patients lived overall was also similar: about 19.29 months for Treatment A and 21.45 months for Comparator B.\n- Some side effects were different between the two treatments. For example, more people on Treatment A had low white blood cell counts, while more people on Comparator B had diarrhea and mouth sores.\n\n**Conclusion:**\nIn the end, Treatment A"
    },
    {
        "id": "42",
        "PMID": "20087643",
        "title": "A bupropion smoking cessation clinical trial for cancer patients",
        "journal": "Cancer Causes Control",
        "abstract": "Objective:\nMany cancer patients continue to smoke postdiagnosis, yet there have been few smoking cessation trials for this population.\nMethods:\nThis double\u2010blind placebo\u2010controlled trial randomized 246 cancer patients to 9 weeks of placebo or treatment A, stratifying by pre\u2010treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7\u2010day point\u2010prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects.\nResults:\nThere was no main effect of treatment A vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38\u20104.81, p =0.64). At week 12, the abstinence rates were 24.2% for placebo and 27.2% for treatment A; at week 27, the abstinence rates were 17.4% for placebo and 18.4% for treatment A. There was no statistically significant difference between placebo and treatment A in average daily smoking to week 12 (mean [SE] 5.2 [0.95] vs. 5.3 [1.0]; p=0.97); and to week 27 (mean [SE] 5.4 [0.88] vs. 6.1 [0.90]; p=0.64). There were no statistically significant difference between placebo and treatment A on changes in withdrawals (p=0.39); negative (p=0.41) and positive affect (p=0.77), and physical (p=0.31) and mental (p=0.42) quality of life.\nConclusion:\nTreatment A was not more effective than placebo on the prevalence of abstinence of cancer patients who continue to smoke postdiagnosis.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Summary:**\n\nThis study looked at cancer patients who still smoke after being diagnosed. The researchers wanted to see if a new treatment (called Treatment A) could help them stop smoking better than a fake treatment (placebo). They had 246 patients in the study, and everyone got some help, like patches for nicotine and advice on how to quit.\n\nAfter 12 weeks, about 24% of the patients who got the fake treatment and 27% of those who got Treatment A stopped smoking. After 27 weeks, the numbers were similar: 17% for the fake treatment and 18% for Treatment A. This means that Treatment A didn\u2019t really help people stop smoking any better than the fake treatment.\n\nThe researchers also looked at other things, like how the patients felt and how their lives were going, but they didn\u2019t find any big differences between the two groups. So, in the end, Treatment A didn\u2019t work better than the fake treatment for helping cancer patients quit smoking."
    },
    {
        "id": "41",
        "PMID": "20087643",
        "title": "A bupropion smoking cessation clinical trial for cancer patients",
        "journal": "Cancer Causes Control",
        "abstract": "Objective:\nMany cancer patients continue to smoke postdiagnosis, yet there have been few smoking cessation trials for this population. Depression, which is prevalent among cancer patients, may be a barrier to cessation.\nMethods:\nThis double\u2010blind placebo\u2010controlled trial randomized 246 cancer patients to 9 weeks of placebo or treatment A, stratifying by pre\u2010treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7\u2010day point\u2010prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects.\nResults:\nThere was no main effect of treatment A vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38\u20104.81, p = 0.64). Patients with depression symptoms reported significantly lower abstinence rates vs. patients without depression symptoms (OR = .14, 95% CI: 0.02\u20100.80, p=0.03). Treatment A increased abstinence rates, vs. placebo, more for participants with depression vs. those without depression symptoms. For patients with depression symptoms, treatment A reduced withdrawal symptoms and improved quality of life vs. placebo.\nConclusion:\nFor patients with depression symptoms, treatment increases abstinence rates, lowers withdrawal, and increases quality of life. However, abstinence rates among patients with depression symptoms were low vs. patients without depression symptoms, who exhibited similar abstinence rates when treated with treatment A or transdermal nicotine and counseling alone. These results can guide future smoking cessation intervention studies with cancer patients.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**What the Study is About:**\nSome people with cancer still smoke even after they find out they have cancer. This study wanted to see if a special treatment could help these people stop smoking, especially since many of them feel sad or depressed, which can make it harder to quit.\n\n**How They Did the Study:**\nThe researchers had 246 cancer patients. They gave some of them the special treatment and others a fake treatment (like a sugar pill) for 9 weeks. Everyone also got help with using a nicotine patch and advice on how to quit smoking. They checked to see how many people stopped smoking after the treatment and again 6 months later.\n\n**What They Found:**\n1. The special treatment didn\u2019t help people stop smoking more than the fake treatment did.\n2. People who felt sad or depressed had a much harder time quitting compared to those who didn\u2019t feel sad.\n3. The special treatment did help people who were sad to feel better and made it easier for them to deal with wanting to smoke.\n\n**Conclusion:**\nEven though the special treatment didn\u2019t work for everyone, it did help some people who were feeling sad. The study shows that it\u2019s important to think about how people\u2019s feelings can affect their ability to quit smoking, especially for cancer patients.\n\n**Important Note:**\nSometimes, when studies are shared, they might make things sound better than they really are. So, we"
    },
    {
        "id": "21",
        "PMID": "20153039",
        "title": "Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial",
        "journal": "Lancet",
        "abstract": "Background:\nWe aimed to compare overall survival in patients receiving treatment A or comparator B.\nMethods:\nThis was an open\u2010label randomized trial undertaken in 50 centres across eight countries. 1006 treatment\u2010naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimization to receive comparator B or treatment A. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non\u2010stratified log\u2010 rank test. Analysis was by intention to treat. This study is registered, number ISRCTN XXXX.\nFindings:\n502 patients were randomly assigned to receive comparator B and 504 to receive combined treatment A. Median follow\u2010up was 37.2 months (24.8\u201052.3). Median overall survival was 18.8 months (17.0\u201023.2) for patients receiving comparator B versus 18.6 months (16.5\u201020.6) for those receiving treatment A. Overall survival did not differ between the two groups (hazard ratio 1.05 [95% CI 0.90\u20101.21], p=0.55; absolute difference 0.3% (\u20105.1 to 5.6) at 1 year and 2.7% (\u20108.2 to 2.9) at 3 years). Serious adverse events were reported in 113 (23%) patients receiving comparator B and 131 (26%) of those receiving combined treatment A.\nInterpretation:\nAlthough treatment A does not improve overall or progression\u2010free survival compared with comparator B, treatment A might still have a role because it can produce remissions that are of clinically relevant length in some patients. Identification of patients who will benefit from treatment A is crucial.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nScientists wanted to see if two different treatments helped people with a serious kind of kidney cancer live longer. They did a big test with over 1,000 patients from different countries. Half of the patients got treatment A, and the other half got treatment B. \n\nAfter watching the patients for about 3 years, they found that both treatments helped people live about the same amount of time\u2014around 18 months. So, there wasn\u2019t a big difference between the two treatments in how long people lived. \n\nSome patients had serious side effects from both treatments, but a few more had side effects from treatment A. \n\nEven though treatment A didn\u2019t help people live longer overall, it might still be useful for some patients because it can help them feel better for a while. The scientists think it\u2019s important to find out which patients might benefit from treatment A.\n\nLastly, they mentioned that sometimes people can twist the results of studies to make them sound better than they really are, so we should be careful about how we understand these findings."
    },
    {
        "id": "22",
        "PMID": "20153039",
        "title": "Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial",
        "journal": "Lancet",
        "abstract": "Background:\nWe aimed to compare overall survival in patients receiving treatment A or comparator B.\nMethods:\nThis was an open\u2010label randomized trial undertaken in 50 centres across eight countries. 1006 treatment\u2010naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimization to receive comparator B or treatment A. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non\u2010stratified log\u2010 rank test. Analysis was by intention to treat. This study is registered, number ISRCTN XXXX.\nFindings:\n502 patients were randomly assigned to receive comparator B and 504 to receive combined treatment A. Median follow\u2010up was 37.2 months (24.8\u201052.3). Median overall survival was 18.8 months (17.0\u201023.2) for patients receiving comparator B versus 18.6 months (16.5\u201020.6) for those receiving treatment A. Overall survival did not differ between the two groups (hazard ratio 1.05 [95% CI 0.90\u20101.21], p=0.55; absolute difference 0.3% (\u20105.1 to 5.6) at 1 year and 2.7% (\u20108.2 to 2.9) at 3 years). There was no evidence that progression free survival differed statistically between treatment groups (HR 1.02 [0.89\u20131.16]; p=0.81). During treatment significantly more grade 3 and 4 toxic effects were associated with combined treatment A than with comparator B (269 patients [53%] vs. 183 patients [36%]; p<0.0001). Serious adverse events were reported in 113 (23%) patients receiving comparator B and 131 (26%) of those receiving combined treatment A.\nInterpretation:\nTreatment A was not more effective than comparator B on overall survival in patients diagnosed with advanced metastatic renal cell carcinoma.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nScientists wanted to see if two different treatments for a type of kidney cancer helped people live longer. They did a big test with 1,006 people who had never been treated before. Half of the people got Treatment A, and the other half got Treatment B. The doctors knew which treatment each person was getting, but the study was set up to be fair.\n\nAfter following the patients for about 3 years, they found that both treatments helped people live about the same amount of time. The average time people lived was about 18.8 months for Treatment B and 18.6 months for Treatment A, which is almost the same. They also looked at how many people had serious side effects from the treatments. More people who got Treatment A had bad side effects compared to those who got Treatment B.\n\nIn the end, the study showed that Treatment A didn\u2019t help people live longer than Treatment B, and it had more side effects. So, Treatment B might be a better choice for patients with this kind of cancer."
    },
    {
        "id": "59",
        "PMID": "20448107",
        "title": "Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma",
        "journal": "Blood",
        "abstract": "In this double\u2010blind, placebo\u2010controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan\u2010prednisone and treatment A or melphalan\u2010prednisone and placebo. The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. A total of 357 patients were analyzed. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the treatment A and placebo arms, respectively (P < .001). There was no significant difference in progression\u2010free or overall survival, with median survival being 29 months in the treatment A arm and 32 months in the placebo arm. Most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the treatment A arm. Constipation, neuropathy, non\u2010neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the treatment A arm. The number of thromboembolic events was equal in the 2 treatment arms. In conclusion, treatment A had a significant antimyeloma effect, but this did not translate into improved survival.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simpler summary of the study for your fifth grader:\n\nThis study looked at a new treatment for a type of cancer called multiple myeloma. They had 363 patients who were split into two groups. One group got the new treatment along with some medicine called melphalan and prednisone, while the other group got the same melphalan and prednisone but with a fake treatment (placebo).\n\nThe doctors wanted to see how well the new treatment worked. They found that about 34% of the patients who got the new treatment showed some improvement, while 33% of the patients who got the fake treatment also showed improvement. So, both groups did about the same in terms of feeling better.\n\nHowever, when they looked at how long people lived after the treatment, they found that those who got the new treatment lived about 29 months on average, while those who got the fake treatment lived about 32 months. So, the new treatment didn\u2019t help people live longer.\n\nThey also noticed that people who got the new treatment had more problems like constipation and other side effects compared to those who got the fake treatment. \n\nIn the end, the new treatment seemed to help a little bit, but it didn\u2019t make people live longer or feel better overall. The study suggests that we should be careful when looking at results like this, especially if they seem too good to be true."
    },
    {
        "id": "60",
        "PMID": "20448107",
        "title": "Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma",
        "journal": "Blood",
        "abstract": "In this double\u2010blind, placebo\u2010controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan\u2010prednisone and treatment A or melphalan\u2010prednisone and placebo. The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. The primary outcome was overall survival. A total of 357 patients were analyzed. The median survival was 29 months (95% [CI], 25\u201038 months) in the treatment A arm and 32 months (95% [CI], 27\u201038 months) in the placebo arm; p=0.35. There was no statistically significant difference in progression free survival between the 2 arms with medians of 15 months 95% CI [12\u201019] for the treatment A arm and 14 months 95% CI [11\u201018] for the placebo arm. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the treatment A and placebo arms, respectively (P < .001). Constipation, neuropathy, non\u2010neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the treatment A arm. The number of thromboembolic events was 8% in both arms. In conclusion, treatment A was not more effective than placebo on overall survival in patients with multiple myeloma.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nThis study looked at a new treatment for a type of cancer called multiple myeloma. They wanted to see if this new treatment (let's call it Treatment A) was better than a fake treatment (called a placebo) when given with some medicine called melphalan and prednisone.\n\nThey had 363 people in the study, but they ended up looking at the results of 357 of them. They found that people who got Treatment A lived for about 29 months on average, while those who got the placebo lived for about 32 months. This means that there wasn't a big difference in how long people lived between the two groups.\n\nThey also checked how long people could live without their cancer getting worse. Both groups had similar results, with Treatment A lasting about 15 months and the placebo about 14 months.\n\nSome people got better from their cancer, but the numbers were pretty close: 34% of those on Treatment A got better, and 33% of those on the placebo did too. However, more people who took Treatment A had side effects like constipation and skin problems.\n\nIn the end, the study showed that Treatment A didn\u2019t help people live longer than the placebo, so it wasn\u2019t more effective for treating this type of cancer. \n\nSo, the main point is that the new treatment didn\u2019t work better than the fake treatment, and it also caused more side effects."
    },
    {
        "id": "50",
        "PMID": "20530276",
        "title": "Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nWe sought to determine whether treatment A improved overall survival (OS) compared with comparator B in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.\nPatients and methods:\nA total of 1,221 patients with MBC previously treated with anthracycline and taxanes were randomly assigned to treatment A or comparator B (2,500 mg/m2 on the same schedule) given every 21 days. The trial was powered to detect a 20% reduction in the hazard ratio (HR) for death.\nResults:\nThere was no significant difference in OS between the treatment A and comparator B arm, the primary end point (median, 16.4 v 15.6 months; HR = 0.9; 95% CI, 078 to 1.03; P = .1162). The arms were well balanced with the exception of a higher prevalence of impaired performance status (Karnofsky performance status 70% to 80%) in the treatment A arm (32% v 25%). Grade 3 to 4 neuropathy occurred in 24% treated with the treatment A compared to 1.2% treated with comparator B. The median time to improvement of grade 3 or worse treatment related neuropathy by at least one grade was 4.5 weeks. Grade 3\u20104 neutropenia and grade 3\u20104 febrile neutropenia occurred in 73% and 7% treated with the treatment A versus 9% and 0.6% treated with comparator B. Grade 3\u20104 fatigue occurred in 12% treated with the treatment A versus 3% treated with comparator B.\nConclusion:\nThe treatment A was not more effective than comparator B on overall survival in patients with metastatic breast cancer previously treated with anthracycline and taxanes.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose:** The researchers wanted to find out if a new medicine (let's call it Treatment A) helps people with a type of breast cancer live longer compared to another medicine (we'll call it Comparator B). The people in the study had already received other treatments before.\n\n**Patients and Methods:** They studied 1,221 patients who had this type of cancer and had already been treated with two specific types of medicines. The patients were randomly split into two groups: one group got Treatment A, and the other group got Comparator B. They received their treatments every 21 days.\n\n**Results:** After looking at the results, the researchers found that there was no big difference in how long people lived between the two groups. On average, people taking Treatment A lived for about 16.4 months, while those taking Comparator B lived for about 15.6 months. They also noticed that more people taking Treatment A had some side effects, like feeling very tired or having nerve problems.\n\n**Conclusion:** In the end, Treatment A did not help people live longer than Comparator B for those with this type of breast cancer who had already been treated before.\n\nThe passage also mentions that sometimes people might try to make a study sound better than it really is by focusing on less important results. But in this case, the study was clear and didn\u2019t have that kind of misleading information."
    },
    {
        "id": "49",
        "PMID": "20530276",
        "title": "Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nWe sought to determine whether treatment A improved overall survival (OS) compared with comparator B in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.\nPatients and methods:\nA total of 1,221 patients with MBC previously treated with anthracycline and taxanes were randomly assigned to treatment A or comparator B (2,500 mg/m2 on the same schedule) given every 21 days. The trial was powered to detect a 20% reduction in the hazard ratio (HR) for death.\nResults:\nThere was no significant difference in OS between the treatment A and comparator B arm, the primary end point (median, 16.4 v 15.6 months; HR = 0.9; 95% CI, 078 to 1.03; P = .1162). The arms were well balanced with the exception of a higher prevalence of impaired performance status (Karnofsky performance status 70% to 80%) in the treatment A arm (32% v 25%). In a secondary Cox regression analysis adjusted for performance status and other prognostic factors, OS was improved for the treatment A (HR = 0.85; 95% CI, 0.75 to 0.98; P = .0231). In 79% of patients with measurable disease, the treatment A significantly improved progression\u2010free survival (PFS; median, 6.2 v 4.2 months; HR = 0.79; P = .0005) and response rate (43% v 29%; P < .0001). Grade 3 to 4 neuropathy occurred in 24% treated with the treatment A combination, but was reversible.\nConclusion:\nThis study confirmed a previous trial demonstrating improved PFS and response for the treatment A compared with comparator B alone, although this did not result in improved survival.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose of the Study:**\nThe researchers wanted to find out if a new treatment (let's call it Treatment A) helps people with a type of breast cancer live longer compared to another treatment (we'll call it Treatment B).\n\n**What They Did:**\nThey studied 1,221 patients who had already received other cancer treatments. These patients were randomly split into two groups: one group got Treatment A, and the other group got Treatment B. They checked how long the patients lived after starting the treatments.\n\n**What They Found:**\n1. **Living Longer:** The study showed that there wasn't a big difference in how long people lived between the two treatments. On average, people on Treatment A lived about 16.4 months, while those on Treatment B lived about 15.6 months. This difference wasn't considered important.\n   \n2. **Other Results:** However, when they looked at some other details, they found that people on Treatment A did better in some ways:\n   - They had a longer time without their cancer getting worse (6.2 months for Treatment A vs. 4.2 months for Treatment B).\n   - More people on Treatment A had their cancer shrink (43% vs. 29%).\n\n3. **Side Effects:** Some people who took Treatment A had serious nerve problems, but these problems went away after stopping the treatment.\n\n**Conclusion:**\nEven though Treatment A helped some"
    },
    {
        "id": "24",
        "PMID": "20564068",
        "title": "A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study",
        "journal": "Cancer",
        "abstract": "Background:\nCancer\u2010related fatigue is a debilitating symptom affecting psychosocial functioning and quality of life in 70% to 100% of cancer patients during and after treatment. The authors examined the effect of 200 mg of treatment A compared to placebo on the severity of cancer\u2010related fatigue.\nMethods:\nThe authors conducted a multicenter, randomized, double\u2010blind, placebo\u2010 controlled, phase 3, clinical trial to examine the effect of treatment A on patient\u2010 reported fatigue in cancer patients undergoing chemotherapy. A sample of 877 cancer patients beginning chemotherapy at 23 geographically separate University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) affiliates were assessed for fatigue. Patients who reported fatigue (N = 867) were randomly assigned to receive either treatment A or a placebo. Treatment began on Day 5 of Cycle 2 and ended after Day 7 of Cycle 4. Fatigue, sleepiness and depression were assessed during Cycles 2 to 4 by using psychometrically valid measures. The primary outcome was the worst level of cancer related fatigue during the previous week at Cycle 4. Group differences (treatment vs. placebo) were examined by using an analysis of covariance (ANCOVA) adjusting for baseline fatigue (Cycle 2).\nResults:\nThere were 631 patients (315 treatment A, 316 placebo) who provided evaluable data and were analyzed. There was no statistical significant difference for the worst level of cancer related fatigue between treatment A (mean (SE) = 6.87 (0.14) and placebo (mean (SE) = 7.09 (0.13); p = 0.08. Sleepiness was statistically significantly higher in placebo (mean (SE) = 18.38 (0.31) vs. treatment A (mean (SE) = 16.82 (0.26); p = 0.002. Treatment A had no statistically significant effect on depression (p=0.87)\nConclusion:\nTreatment A was not more effective than placebo in controlling cancer\u2010related fatigue.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nThis study looked at how a new medicine, called treatment A, affects tiredness in people who have cancer and are getting treatment. Many cancer patients feel very tired, and the researchers wanted to see if treatment A could help with that.\n\nThey had 877 cancer patients who were starting their treatment. Out of those, 867 patients said they felt tired, so they were split into two groups. One group got treatment A, and the other group got a fake medicine (called a placebo) that didn\u2019t do anything. The patients didn\u2019t know which medicine they were getting, and neither did the doctors, which helps make the results fair.\n\nThey checked how tired the patients felt during their treatment. After looking at the results, they found that there wasn\u2019t a big difference in how tired the two groups felt. The people who took treatment A felt just as tired as those who took the fake medicine. They also found that the people who took the fake medicine felt sleepier than those who took treatment A, but treatment A didn\u2019t help with feelings of sadness.\n\nIn the end, the researchers concluded that treatment A didn\u2019t work better than the fake medicine for helping with tiredness in cancer patients. So, it seems like this new medicine isn\u2019t helpful for that problem."
    },
    {
        "id": "23",
        "PMID": "20564068",
        "title": "A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study",
        "journal": "Cancer",
        "abstract": "Background:\nCancer\u2010related fatigue is a debilitating symptom affecting psychosocial functioning and quality of life in 70% to 100% of cancer patients during and after treatment. The authors examined the effect of treatment A on the severity of cancer\u2010related fatigue.\nMethods:\nThe authors conducted a multicenter, randomized, double\u2010blind, placebo\u2010 controlled, phase 3, clinical trial to examine the effect of treatment A on patient\u2010 reported fatigue in cancer patients undergoing chemotherapy. A sample of 877 cancer patients beginning chemotherapy at 23 geographically separate University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) affiliates were assessed for fatigue. Patients who reported fatigue (N = 867) were randomly assigned to receive either treatment A or a placebo. Treatment began on Day 5 of Cycle 2 and ended after Day 7 of Cycle 4. Fatigue and depression were assessed during Cycles 2 to 4 by using psychometrically valid measures. Group differences (treatment vs. control) in the worst level of fatigue during the previous week at Cycle 4 were examined by using an analysis of covariance (ANCOVA) adjusting for baseline fatigue (Cycle 2).\nResults:\nThere were 631 patients (315 treatment A, 316 placebo) who provided evaluable data. ANCOVA showed a significant interaction between treatment condition and baseline fatigue (P = .017), where patients with severe baseline fatigue (n = 458) benefited from treatment A, whereas patients with mild or moderate fatigue did not. Treatment A had no statistically significant effect on depression (P > .05).\nConclusions:\nTreatment A may be useful in controlling cancer\u2010related fatigue in patients who present with severe fatigue but is not useful in patients with mild or moderate fatigue.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\nThis study looked at how a new treatment, called Treatment A, helps people with cancer who feel very tired because of their illness and the medicine they take. Many cancer patients feel really tired, and this can make it hard for them to enjoy life.\n\nThe researchers wanted to see if Treatment A could help these tired patients feel better. They had a lot of people in the study\u2014877 cancer patients\u2014and they split them into two groups. One group got Treatment A, and the other group got a fake treatment (like a sugar pill) that wouldn\u2019t help them.\n\nThey checked how tired the patients felt during their treatment. They found that Treatment A helped people who were very tired at the start feel less tired after a while. But it didn\u2019t help people who were only a little tired. Also, Treatment A didn\u2019t seem to help with feelings of sadness.\n\nIn the end, the researchers think Treatment A could be good for people who are really, really tired from cancer, but it doesn\u2019t help those who are just a bit tired. \n\nThe passage also warns that sometimes studies can be presented in a way that makes them sound better than they really are, so we should be careful about believing everything we read."
    },
    {
        "id": "10",
        "PMID": "20673585",
        "title": "Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial",
        "journal": "Leuk Res",
        "abstract": "This prospective multicenter phase III clinical trial was designed to assess efficacy and safety of treatment A as an adjunct to de novo AML remission induction therapy (www.clinicaltrials.gov. NCTXXXXX). The primary outcomes were response to induction and overall survival (OS) at 3 years. The characteristics of the 260 patients randomized to cytarabine and idarubicine with treatment A or cytarabine and idarubicine alone (control arm) were similar in both arms. 62.5% of patients randomized in the treatment A arm had a complete response to induction vs. 64.6% in the control arm; p=0.72. The three\u2010year OS rates were not statistically significantly different between treatment A and control arm (25.6 +/\u2010 5.1% vs. 31.8 +/\u2010 5.6%; p=0.38. Treatment A as an adjunct to cytarabine and idarubicine was not more effective than cytarabine and idarubicine alone in acute myeloid leukemia patients.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\nThis study looked at a new treatment (called Treatment A) to see if it helps people with a type of blood cancer called acute myeloid leukemia (AML) when they are starting their main treatment. The researchers wanted to find out if this new treatment was better than just using the regular medicines, which are called cytarabine and idarubicine.\n\nThey included 260 patients in the study. Some got the new treatment along with the regular medicines, and some only got the regular medicines. They found that about the same number of people got better with both treatments. After three years, the chance of being alive was also similar for both groups.\n\nIn the end, the study showed that Treatment A didn\u2019t work better than the regular medicines alone for these patients. The researchers also warned that sometimes people might try to make a study sound better than it really is, so it\u2019s important to be careful when reading about these results."
    },
    {
        "id": "9",
        "PMID": "20673585",
        "title": "Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial",
        "journal": "Leuk Res",
        "abstract": "This prospective multicenter phase III clinical trial was designed to assess efficacy and safety of treatment A as an adjunct to de novo AML remission induction therapy (www.clinicaltrials.gov. NCTXXXXX). Patients' characteristics were similar in both arms. Treatment A improved severity and duration of leukopenia. Three\u2010 year OS were similar (25.6 +/\u2010 5.1% vs. 31.8 +/\u2010 5.6%) in both arms except for patients with myeloblastic features. Significant factors for better survival were the use of treatment A (p = 0.049), female sex (p = 0.05) and single induction cycle (p < 0.001) in multivariate analysis. Female patients performed better than male patients. Better survival obtained among female AML patients needs to be validated within the context of cytogenetic analysis.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary for your fifth grader:\n\nThis passage talks about a study that looked at a new treatment (let's call it Treatment A) for a type of blood cancer called AML. The researchers wanted to see if Treatment A helped people feel better and live longer when they were getting their first treatment for AML.\n\nIn the study, they found that Treatment A helped reduce a problem called leukopenia, which means having low white blood cells. However, when they looked at how long people lived after three years, the results were pretty similar for both groups of patients, whether they got Treatment A or not. But they noticed that women did better than men in this study.\n\nThe researchers also found that some things, like being a woman and having just one round of treatment, seemed to help people live longer. But they need to check more to understand why women did better.\n\nFinally, the passage warns that sometimes studies can be tricky. They might highlight certain results to make them sound better than they really are, so we should be careful and think critically about what the study is saying."
    },
    {
        "id": "30",
        "PMID": "20800381",
        "title": "Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4",
        "journal": "Int J Radiat Oncol Biol Phys",
        "abstract": "Purpose:\nA two\u2010arm, double\u2010blind, randomized trial was performed to evaluate the effect of treatment A on acute skin\u2010related toxicity in patients undergoing breast or chest wall radiotherapy.\nMethods and material:\nPatients with ductal carcinoma in situ or invasive breast carcinoma who were undergoing external beam radiotherapy to the breast or chest wall were randomly assigned to apply treatment A or placebo cream daily. The primary study endpoint was the provider assessed maximal grade of Common Terminology Criteria for Adverse Events, version 3.0, radiation dermatitis.\nResults:\nA total of 176 patients were enrolled between September 21, 2007, and December 7, 2007. The provider assessed primary endpoint showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2+/\u20100.85 for treatment A vs. 1.3+/\u20100.80 for placebo; p = .18). Severe radiation dermatitis concerned 4 (5%) in both arms; p=.97. The worst grade of any type of toxicity were respectively in the placebo and treatment A groups 9% vs. 2% for grade 3 or 4: 24% vs. 30% for grade 2; 61% vs. 40% for grade 1; and 6% vs. 27% for grade 0; p = .04. For the patient\u2010reported outcome, the maximum Skindex\u201016 score for the treatment A group did not differ between the MMF arm (mean = 1.4) vs. placebo arm (mean = 1.7); p=0.07. The mean score for overall quality of life was 8.3 for treatment A vs. 8.4 for placebo; P> .05. The maximal Skin Toxicity Assessment Tool score was respectively in the treatment A and placebo group 1.5 vs. 2.1 for discomfort or burning (p=.02); 1.5 vs. 2.2 for itching (p = .002), 1.0 vs. 1.4 for pulling (p=.07) and 2.1 vs. 2.5 for discomfort or tenderness (p=.11).\nConclusion:\nTreatment A during radiotherapy was not more effective than placebo on acute skin related toxicity in patients undergoing breast or chest wall radiotherapy.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose of the Study:**\nThe researchers wanted to see if a special cream (called treatment A) could help people who were getting radiation therapy for breast cancer. They were looking to find out if the cream could reduce skin problems that sometimes happen because of the treatment.\n\n**How They Did It:**\nThey took a group of 176 patients who had breast cancer and randomly divided them into two groups. One group used the special cream, and the other group used a fake cream (placebo) that didn\u2019t have any medicine in it. They checked how bad the skin problems were for both groups.\n\n**What They Found:**\nAfter looking at the results, they found that there wasn\u2019t much difference between the two groups. The skin problems were about the same for people using the special cream and those using the fake cream. They also looked at how the patients felt about their skin and their overall quality of life, and again, there wasn\u2019t a big difference.\n\n**Conclusion:**\nIn the end, the special cream didn\u2019t work better than the fake cream for helping with skin problems during radiation therapy for breast cancer.\n\nSo, the study showed that the cream didn\u2019t really help, and it\u2019s important to be careful when reading about studies to make sure they\u2019re not trying to make something sound better than it really is."
    },
    {
        "id": "29",
        "PMID": "20800381",
        "title": "Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4",
        "journal": "Int J Radiat Oncol Biol Phys",
        "abstract": "Purpose:\nA two\u2010arm, double\u2010blind, randomized trial was performed to evaluate the effect of treatment A on acute skin\u2010related toxicity in patients undergoing breast or chest wall radiotherapy.\nMethods and materials:\nPatients with ductal carcinoma in situ or invasive breast carcinoma who were undergoing external beam radiotherapy to the breast or chest wall were randomly assigned to apply treatment A or placebo cream daily. The primary study endpoint was the provider assessed maximal grade of Common Terminology Criteria for Adverse Events, version 3.0, radiation dermatitis. The secondary endpoints included provider\u2010assessed Common Terminology Criteria for Adverse Events Grade 3 or greater radiation dermatitis and adverse event monitoring. The patient\u2010reported outcome measures included the Skindex\u201016, the Skin Toxicity Assessment Tool, a Symptom Experience Diary, and a quality\u2010of\u2010 life self\u2010assessment. An assessment was performed at baseline, weekly during radiotherapy, and for 2 weeks after radiotherapy.\nResults:\nA total of 176 patients were enrolled between September 21, 2007, and December 7, 2007. The provider assessed primary endpoint showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2 for treatment A vs. 1.3 for placebo; p = .18). Common Terminology Criteria for Adverse Events toxicity was greater in the placebo group (p = .04), primarily from pruritus. For the patient\u2010reported outcome measures, the maximum Skindex\u201016 score for the treatment A group showed less itching (p = .008), less irritation (p = .01), less symptom persistence or recurrence (p = .02), and less annoyance with skin problems (p = .04). The group\u2019s maximal Skin Toxicity Assessment Tool score showed less burning sensation (p = .02) and less itching (p = .002).\nConclusion:\nPatients receiving daily treatment A during radiotherapy might experience reduced acute skin toxicity compared with patients receiving placebo.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose of the Study:**\nThe researchers wanted to see if a special cream (called treatment A) could help people who are getting radiation therapy for breast cancer. They were looking to find out if the cream could reduce skin problems that sometimes happen because of the treatment.\n\n**How They Did It:**\nThey took a group of patients who had breast cancer and randomly gave them either the special cream or a fake cream (placebo) to use every day while they were getting radiation. They checked how bad the skin problems were at different times during and after the treatment.\n\n**What They Found:**\n- They had 176 patients in the study.\n- The doctors didn\u2019t see a big difference in the worst skin problems between the two groups (the cream group and the fake cream group).\n- However, the people using the fake cream reported more itching and discomfort.\n- Those using the special cream said they had less itching, less irritation, and felt better about their skin problems.\n\n**Conclusion:**\nUsing the special cream might help people feel better and have fewer skin problems while they are getting radiation therapy compared to those using the fake cream.\n\n**Important Note:**\nSometimes, studies can be presented in a way that makes the results sound better than they really are. So, it\u2019s important to be careful when looking at these kinds of studies and think critically about what the results really mean."
    },
    {
        "id": "55",
        "PMID": "20973267",
        "title": "Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer",
        "journal": "Int J Gynecol Cancer",
        "abstract": "Objective:\nTo evaluate the safety and efficacy of treatment A in combination with pegylated liposomal doxorubicin (PLD) in platinum\u2010resistant ovarian cancer (OC).\nMethods:\nPatients with platinum\u2010refractory or \u2010resistant primary or secondary) OC were randomized to receive treatment A and PLD at 50 mg/m2 intravenously or PLD alone at 50 mg/m2 intravenously on day 1 every 28 days until tumor progression or unacceptable toxicity. The primary end point was progression\u2010free survival (PFS). Other end points were objective response rate and safety. The study was originally planned for 244 patients. The trial was temporarily placed on hold after 125 patients were randomized while the results of another trial were being reviewed and the sponsor decided not to resume enrollment. The interim analysis became the final analysis.\nResults:\nThe median PFS was 5.6 months for treatment A + PLD (n = 65) versus 3.7 months for PLD (n = 60) (hazards ratio, 0.92; P = 0.7243). A preplanned subgroup analysis showed that 75 patients with platinum\u2010refractory or primary platinum\u2010resistant OC had a median PFS of 5.6 months for treatment A + PLD versus 2.9 months for PLD (hazards ratio, 0.55; P = 0.0425). Hematologic adverse events were 66% on the treatment A + PLD arm versus 44% on the PLD arm, manageable with dose reductions. Nonhematologic adverse events were similar for both arms. The incidence of palmar\u2010plantar erythrodysesthesia and stomatitis was lower on treatment A + PLD (23%, 31%, respectively) versus (39%, 49%, respectively) on PLD.\nConclusion:\nOverall median PFS showed a positive trend but was not statistically significant. The median PFS in the platinum\u2010refractory and primary platinum\u2010resistant OC patients was significantly longer for treatment A + PLD versus PLD. Treatment A may ameliorate the palmar\u2010plantar erythrodysesthesia and stomatitis known to be associated with PLD. Further study of this active well\u2010tolerated regimen in platinum\u2010refractory and primary platinum\u2010resistant OC is planned. This study was registered at www.clinicaltrials.gov",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**What the Study Was About:**\nThe researchers wanted to see if a new treatment (let's call it Treatment A) combined with a medicine called PLD could help women with a type of cancer called ovarian cancer that doesn\u2019t respond well to a common treatment called platinum.\n\n**How They Did It:**\nThey took a group of women with this tough kind of cancer and split them into two groups. One group got Treatment A with PLD, and the other group just got PLD. They gave the medicines through an IV (a tube in their arm) every 28 days until the cancer got worse or the side effects were too much to handle.\n\n**What They Found:**\n- The women who got Treatment A with PLD had their cancer stay the same for about 5.6 months, while those who only got PLD had it stay the same for about 3.7 months.\n- For a special group of women who had the hardest-to-treat cancer, those who got Treatment A with PLD did even better, lasting about 5.6 months compared to just 2.9 months for those who only got PLD.\n- However, the overall results weren\u2019t strong enough to say for sure that Treatment A was better for everyone.\n- Some side effects, like skin problems, were less common in the group that got Treatment A with PLD.\n\n**Conclusion:**\nThe study suggests"
    },
    {
        "id": "56",
        "PMID": "20973267",
        "title": "Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer",
        "journal": "Int J Gynecol Cancer",
        "abstract": "Objective:\nTo evaluate the safety and efficacy of treatment A in combination with pegylated liposomal doxorubicin (PLD) in platinum\u2010resistant ovarian cancer (OC).\nMethods:\nPatients with platinum\u2010refractory or \u2010resistant primary or secondary) OC were randomized to receive treatment A and PLD at 50 mg/m2 intravenously or PLD alone at 50 mg/m2 intravenously on day 1 every 28 days until tumor progression or unacceptable toxicity. The primary end point was progression\u2010free survival (PFS). Other end points were objective response rate, and safety. The study was originally planned for 244 patients. The trial was temporarily placed on hold after 125 patients were randomized while the results of another trial were being reviewed and the sponsor decided not to resume enrollment. The interim analysis became the final analysis.\nResults:\nThe median PFS was 5.6 months for treatment A + PLD (n = 65) versus 3.7 months for PLD (n = 60) (hazards ratio, 0.92; P = 0.7243). ORR was 12.3% for treatment A + PLD vs. 8.3% for PLD, p=0.5640. Hematologic adverse events were 66% on the treatment A + PLD arm versus 44% on the PLD arm with neutropenia 40.0% vs. 22.8%; thrombopenia 33.8% vs. 7.0%; febrile neutropenia10.8% vs. 3.5%. Nonhematologic adverse events were similar for both arms. The incidence of palmar\u2010plantar erythrodysesthesia and stomatitis was lower on treatment A + PLD (23%, 31%, respectively) versus (39%, 49%, respectively) on PLD. The incidence of nausea and fatigue was higher in treatment A + PLD 60.0% vs. 49.1% and 43.1% vs. 36.8%).Thirteen deaths caused by serious adverse event were reported 7 with treatment A + PLD vs. 6 with PLD.\nConclusion:\nTreatment A in combination with pegylated liposomal doxorubicin was not more effective than pegylated liposomal doxorubicin alone in patients with platinum\u2010 resistant ovarian cancer. This study was registered at www.clinicaltrials.gov",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**What the Study Was About:**\nThe researchers wanted to see if a new treatment (let's call it Treatment A) combined with a medicine called PLD could help people with a type of cancer called platinum-resistant ovarian cancer. They wanted to find out if this combination was safer and worked better than just using PLD alone.\n\n**How They Did the Study:**\nThey took a group of patients with this type of cancer and split them into two groups. One group got Treatment A along with PLD, and the other group just got PLD. They gave the treatments every 28 days and kept track of how long the patients stayed healthy without the cancer getting worse.\n\n**What They Found:**\n- The patients who got Treatment A with PLD stayed healthy for about 5.6 months before the cancer got worse, while those who only got PLD stayed healthy for about 3.7 months.\n- However, the difference wasn\u2019t big enough to say that Treatment A really helped more than just PLD.\n- They also looked at how many patients got better and found that 12.3% of the first group got better compared to 8.3% in the second group, but again, this wasn\u2019t a big enough difference to be sure it was because of Treatment A.\n- Some side effects (bad reactions to the medicine) were more common in the group that got Treatment A, like low"
    },
    {
        "id": "25",
        "PMID": "21041710",
        "title": "Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III trial assesses whether treatment A increases the duration of functional independence after surgery or radiosurgery of brain metastases.\nPatients and methods:\nPatients with one to three brain metastases of solid tumors (small\u2010cell lung cancer excluded) with stable systemic disease or asymptomatic primary tumors and WHO performance status (PS) of 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to treatment A or observation (OBS). The primary end point was time to WHO PS deterioration to more than 2.\nResults:\nOf 359 patients, 199 underwent radiosurgery, and 160 underwent surgery. In the radiosurgery group, 100 patients were allocated to OBS, and 99 were allocated to treatment A. After surgery, 79 patients were allocated to OBS, and 81 were allocated to treatment A. The median time to WHO PS more than 2 was 10.0 months (95% CI, 8.1 to 11.7 months) after OBS and 9.5 months (95% CI, 7.8 to 11.9 months) after treatment A (P = .71). Overall survival was similar in the treatment A and OBS arms (median, 10.9 v 10.7 months, respectively; P = .89). Treatment A reduced the 2\u2010year relapse rate both at initial sites (surgery: 59% to 27%, P < .001; radiosurgery: 31% to 19%, P = .040) and at new sites (surgery: 42% to 23%, P = .008; radiosurgery: 48% to 33%, P = .023). Salvage therapies were used more frequently after OBS than after treatment A. Intracranial progression caused death in 78 (44%) of 179 patients in the OBS arm and in 50 (28%) of 180 patients in the treatment A arm.\nConclusion:\nAfter radiosurgery or surgery of a limited number of brain metastases, treatment A reduces intracranial relapses and neurologic deaths but fails to improve the duration of functional independence and overall survival.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose of the Study:**\nThe study wanted to find out if a new treatment (let's call it Treatment A) helps people stay independent and healthy for longer after they have surgery or special radiation for brain tumors.\n\n**What They Did:**\nThey looked at 359 patients who had one to three brain tumors. These patients were treated with either surgery or radiation. Then, they randomly split the patients into two groups: one group got Treatment A, and the other group just watched and waited (this is called observation). They wanted to see how long it took for the patients to get worse.\n\n**What They Found:**\n- Out of the 359 patients, some had surgery and some had radiation.\n- They found that the time before patients got worse was about the same for both groups (around 10 months).\n- The overall survival time (how long people lived) was also similar for both groups (about 11 months).\n- However, Treatment A did help reduce the number of times the tumors came back in the brain and helped people live longer without brain problems.\n\n**Conclusion:**\nEven though Treatment A helped with some things, it didn\u2019t make people stay independent or live longer overall after their surgery or radiation. \n\n**Important Note:**\nSometimes, when studies are shared, they might highlight the good things too much and not talk enough about the not-so-good things. So, it\u2019s important to be"
    },
    {
        "id": "26",
        "PMID": "21041710",
        "title": "Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III trial assesses whether treatment A increases the duration of functional independence after surgery or radiosurgery of brain metastases.\nPatients and methods:\nPatients with one to three brain metastases of solid tumors (small\u2010cell lung cancer excluded) with stable systemic disease or asymptomatic primary tumors and WHO performance status (PS) of 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to treatment A or observation (OBS). The primary end point was time to WHO PS deterioration to more than 2.\nResults:\nOf 359 patients, 179 were allocated to OBS (100 who underwent radiosurgery and 79 who underwent surgery) and 180 to treatment A (99 who underwent radiosurgery and 81 who underwent surgery). The median time to WHO PS more than 2 was 10.0 months (95% CI, 8.1 to 11.7 months) after OBS and 9.5 months (95% CI, 7.8 to 11.9 months) after treatment A (HR= 0.96; 95% CI (0.76\u20101.20); P = .71). Overall survival did not differ in the treatment A and OBS arms (median, 10.9 v 10.7 months, respectively; P = .89). Progression free survival was 4.6 months (95% CI, 3.9 to 6.1 months) in treatment A arm vs 3.4 months (95% CI, 3.1 to 3.9 months) in the OBS arm; p=.02. Extracranial progression at 2 years were 63% in the OBS arm vs. 65% in the treatment A arm; p=.73. Intracranial progression was 78% in the OBS arm vs. 48% in the treatment A arm; p<.001. 16 serious adverse events were reported; 13 in treatment A and 3 in OBS arm.\nConclusion:\nTreatment A was not more effective than observation for the primary and most secondary outcomes in patients with one to three brain metastases of solid tumors.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose of the Study:**\nThe researchers wanted to find out if a new treatment (let's call it Treatment A) helps people with brain tumors live more independently after they have surgery or special radiation treatment.\n\n**Who Was in the Study:**\nThey looked at 359 patients who had one to three brain tumors from solid cancers (but not small-cell lung cancer). These patients were doing okay overall and were treated with either surgery or radiation. Then, they randomly split the patients into two groups: one group got Treatment A, and the other group just had regular check-ups (we'll call this Observation).\n\n**What They Measured:**\nThe main thing they wanted to see was how long it took for the patients to start having more trouble with daily activities (which they measured using a scale called WHO performance status).\n\n**What They Found:**\n- The group that just had check-ups (Observation) had a median time of 10 months before they started having more trouble, while the group that got Treatment A had a median time of 9.5 months.\n- This means that Treatment A didn\u2019t really help people stay independent for longer.\n- Both groups lived about the same amount of time overall (around 10.9 months for Observation and 10.7 months for Treatment A).\n- However, the group that got Treatment A did have a little longer time without their cancer getting worse in some cases (4"
    },
    {
        "id": "43",
        "PMID": "21060024",
        "title": "Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nWe examined the value of treatment A in a phase III trial with strict preoperative staging and surgical resection guidelines.\nPatients and methods:\nPatients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEG II and III) were randomly assigned to treatment A followed by surgery or to surgery alone. To detect with 80% power an improvement in median survival from 17 months with surgery alone to 24 months with treatment A, 282 events were required.\nResults:\nThis trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III. The International Union against Cancer R0 resection rate was 81.9% after treatment A as compared with 66.7% with surgery alone (P = .036). The surgery\u2010only group had more lymph node metastases than the treatment A group (76.5% v 61.4%; P = .018). Postoperative complications were more frequent in the treatment A arm (27.1% v 16.2%; P = .09). After a median follow\u2010up of 4.4 years and 67 deaths, a survival benefit could not be shown (hazard ratio, 0.84; 95% CI, 0.52 to 1.35; P = .466).\nConclusion:\nThis trial showed a significantly increased R0 resection rate but failed to demonstrate a survival benefit. Possible explanations are low statistical power, a high rate of proximal gastric cancer including AEG and/or a better outcome than expected after radical surgery alone due to the high quality of surgery with resections of regional lymph nodes outside the perigastic area (celiac trunc, hepatic ligament, lymph node at a. lienalis; D2).",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simpler summary of the passage for your fifth grader:\n\n**Purpose:** The study wanted to see if a new treatment (let's call it Treatment A) could help people with a type of stomach cancer live longer when combined with surgery.\n\n**What They Did:** They took patients with advanced stomach cancer and randomly split them into two groups. One group got Treatment A before their surgery, and the other group just had surgery without the treatment. They hoped to find out if the people who got Treatment A would live longer than those who only had surgery.\n\n**What They Found:** The study had to stop early because not enough people joined. They had 144 patients instead of the 282 they needed. They found that more people in the Treatment A group had their cancer completely removed during surgery compared to the surgery-only group. However, the group that only had surgery had more cancer spread to their lymph nodes. There were also more problems after surgery for the Treatment A group. After following the patients for about 4.4 years, they didn\u2019t find that Treatment A helped people live longer than just having surgery.\n\n**Conclusion:** Even though Treatment A helped with surgery success, it didn\u2019t help people live longer. The researchers think this might be because they didn\u2019t have enough patients in the study or because the surgery was really good on its own.\n\n**Important Note:** Sometimes, when studies don\u2019t show clear benefits, people might still try to make it sound better than it is. So"
    },
    {
        "id": "44",
        "PMID": "21060024",
        "title": "Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nWe examined the value of treatment A in a phase III trial with strict preoperative staging and surgical resection guidelines.\nPatients and methods:\nPatients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEGII and III) were randomly assigned to treatment A followed by surgery or to surgery alone. The primary outcome was overall survival.\nResults:\nThis trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III. After a median follow\u2010up of 4.4 years and 67 deaths, the median survival was 64.6 months (95% CI, 42.4 to NA) in the treatment A arm versus 52.5 month (95% CI 31.7 to NA) in the surgery alone arm (hazard ratio 0.84; 95% CI, 0.52 to 1.35; P = .466). The survival rate at 2 year was respectively 72.7% (95% CI, 60.7\u201081.7) and 69.9% (95% CI, 57.7\u201079.2) in the treatment A and surgery\u2010only arm. The HR for progression free survival was 0.76 (95% CI, 0.49\u2010 1.16; p=.20). The International Union against Cancer R0 resection rate was 81.9% after treatment A as compared with 66.7% with surgery alone (P = .036). The surgery\u2010only group had more lymph node metastases than the treatment A (76.5% v 61.4%; p = .018). Postoperative complications were more frequent in the treatment A arm (27.1% v 16.2%; P = .09).\nConclusion:\nTreatment A followed by surgery was not more effective than surgery alone on overall survival in patients with locally advanced cancer of the stomach.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\n**Purpose of the Study:**\nThe researchers wanted to see if a new treatment (called Treatment A) could help people with a type of stomach cancer when combined with surgery.\n\n**What They Did:**\nThey took patients who had advanced stomach cancer and randomly divided them into two groups. One group got Treatment A before their surgery, and the other group just had surgery without the treatment. They wanted to find out which group lived longer after their treatment.\n\n**What They Found:**\nThe study had to stop early because not enough people joined. They had 144 patients in total, with about half getting Treatment A and half just having surgery. After following the patients for about 4.4 years, they found that people who got Treatment A lived about 64.6 months on average, while those who only had surgery lived about 52.5 months. However, this difference wasn\u2019t considered strong enough to say Treatment A was better.\n\nThey also looked at other things, like how many people had complications after surgery and how many had cancer spread to nearby lymph nodes. They found that more people in the surgery-only group had cancer spread, but more people in the Treatment A group had complications after surgery.\n\n**Conclusion:**\nIn the end, the researchers decided that Treatment A didn\u2019t help people live longer compared to just having surgery alone.\n\n**Important Note:**\nSometimes, people might try to make a study sound better than"
    },
    {
        "id": "7",
        "PMID": "21399726",
        "title": "The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)",
        "journal": "J Support Oncol",
        "abstract": "Sleep disorders are a substantial problem for cancer survivors, with prevalence estimates ranging from 23% to 61%. Although numerous prescription hypnotics are available, few are approved for long\u2010term use or have demonstrated benefit in this circumstance. Hypnotics may have unwanted side effects and are costly, and cancer survivors often wish to avoid prescription drugs. New options with limited side effects are needed. The purpose of this trial was to evaluate the efficacy of treatment A for sleep in people with cancer who were undergoing cancer treatment. Participants were randomized to receive treatment A or placebo orally 1 hour before bedtime for 8 weeks. The primary end point was area under the curve (AUC) of the overall Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes included the Functional Outcomes of Sleep Questionnaire, the Brief Fatigue Inventory (BFI), and the Profile of Mood States (POMS). Toxicity was evaluated with both self\u2010reported numeric analogue scale questions and the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Questionnaires were completed at baseline and at 4 and 8 weeks. A total of 227 patients were randomized into this study between March 19, 2004, and March 9, 2007, with 119 being evaluable for the primary end point. The AUC over the 8 weeks for treatment A was 51.4 (SD = 16), while that for placebo was 49.7 (SD = 15), with a P value of 0.6957. A supplemental, exploratory analysis revealed that several fatigue end points, as measured by the BFI and POMS, were significantly better for those taking treatment A over placebo. Participants also reported less trouble with sleep and less drowsiness on treatment A than placebo. There were no significant differences in toxicities as measured by self\u2010report or the CTCAE except for mild alkaline phosphatase increases, which were slightly more common in the placebo group. This study failed to provide data to support the hypothesis that treatment A, at bedtime could improve sleep as measured by the PSQI. However, exploratory analyses revealed improvement in some secondary outcomes, such as fatigue. Further research with treatment A exploring physiologic effects in oncology symptom management may be warranted.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simpler summary of the passage for your fifth grader:\n\nThis passage talks about a study that looked at how well a new treatment (let's call it \"treatment A\") helps people with cancer sleep better. Many people who have had cancer have trouble sleeping, and doctors usually give them medicine to help, but those medicines can have side effects and might not be safe to use for a long time.\n\nIn the study, some people got treatment A, and others got a fake treatment (called a placebo) that didn\u2019t actually do anything. They took these treatments for 8 weeks before bedtime. The researchers wanted to see if treatment A helped them sleep better and feel less tired.\n\nAt the end of the study, the results showed that treatment A didn\u2019t really help with sleep as much as they hoped. However, some people who took treatment A said they felt less tired and had a little less trouble sleeping compared to those who took the placebo. There weren\u2019t many side effects from either treatment, but a few more people on the placebo had a slight increase in a certain blood test.\n\nThe researchers said that even though the main goal of the study didn\u2019t show that treatment A helped with sleep, it might still be worth looking into how it helps with tiredness in people with cancer. \n\nLastly, the passage warns that sometimes studies can be presented in a way that makes them sound better than they really are, so we should be careful about believing everything we read."
    },
    {
        "id": "8",
        "PMID": "21399726",
        "title": "The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)",
        "journal": "J Support Oncol",
        "abstract": "Sleep disorders are a substantial problem for cancer survivors, with prevalence estimates ranging from 23% to 61%. Although numerous prescription hypnotics are available, few are approved for long\u2010term use or have demonstrated benefit in this circumstance. Hypnotics may have unwanted side effects and are costly, and cancer survivors often wish to avoid prescription drugs. New options with limited side effects are needed. The purpose of this trial was to evaluate the efficacy of a treatment A for sleep in people with cancer who were undergoing cancer treatment. Participants were randomized to receive treatment A or placebo orally 1 hour before bedtime for 8 weeks. The primary end point was area under the curve (AUC) of the overall Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes included the Functional Outcomes of Sleep Questionnaire, the Brief Fatigue Inventory (BFI), and the Profile of Mood States (POMS). Toxicity was evaluated with both self\u2010reported numeric analogue scale questions and the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Questionnaires were completed at baseline and at 4 and 8 weeks. A total of 227 patients were randomized into this study between March 19, 2004, and March 9, 2007. Twenty\u2010three patients withdrew before starting the study treatment. Primary end\u2010point data were available on 119 patients (62 receiving treatment A and 57 receiving placebo). Baseline characteristics and baseline patient reported outcomes were well balanced between arms. The AUC over the 8 weeks for treatment A was 51.4 (SD = 16 and for placebo was 49.7 (SD = 15), with a P value of 0.7. The FOSQ was not statistically significantly different between groups. There was no statistically significant difference between groups for the POMS week 8 treatment A 6.9 vs. placebo 6.0; p=0.90. For the BFI at week 8 the treatment A and placebo arm scored respectively for fatigue now 22.1 vs. 10.5; p<0.01; for usual fatigue 19.4 vs. 10.0; p=0.05; for worst fatigue 14.8 vs. 12.4; p=0.65; and for activity inference 12.3 vs. 10.8; p=0.75.There were no significant differences in toxicities as measured by self\u2010report or the CTCAE. Treatment A was not more effective than placebo on sleep quality in patients who were undergoing cancer treatment.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the passage for your fifth grader:\n\nThe study looked at how well a new treatment (let's call it \"Treatment A\") helps people with cancer sleep better. Many people who have had cancer have trouble sleeping, and while there are medicines that can help, they can have side effects and are not always safe for long-term use. \n\nIn this study, some people got Treatment A, and others got a fake treatment (called a placebo) that didn\u2019t actually do anything. They took these treatments for 8 weeks before bedtime. The researchers wanted to see if Treatment A helped them sleep better and feel less tired.\n\nThey asked the participants questions about their sleep and how they felt at the beginning of the study and again after 4 and 8 weeks. A total of 227 people started the study, but some left before it began. In the end, they looked at the results for 119 people.\n\nThe results showed that Treatment A didn\u2019t really help people sleep better compared to the placebo. There were no big differences in how well they slept or how tired they felt. Also, there were no serious side effects from either treatment.\n\nSo, the main finding was that Treatment A was not better than the fake treatment for helping cancer patients sleep."
    },
    {
        "id": "5",
        "PMID": "21471562",
        "title": "Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial",
        "journal": "Ann Oncol",
        "abstract": "Background: \nHigh levels of distress and need for self\u2010care information by patients commencing chemotherapy suggest that current prechemotherapy education is suboptimal. We conducted a randomized, controlled trial of a prechemotherapy education intervention (treatment A) to assess impact on patient distress, treatment\u2010related concerns, and the prevalence and severity of and bother caused by six chemotherapy side\u2010effects.\nPatients and methods:\nOne hundred and ninety\u2010two breast, gastrointestinal, and haematologic cancer patients were recruited before the trial closing prematurely (original target 352). Treatment A was administered before first treatment (intervention 1), 48 h after first treatment (intervention 2), and immediately before second treatment (intervention 3). Patient outcomes were measured at baseline (T1: pre\u2010education) and immediately preceding treatment cycles 1 (T2) and 3 (T3).\nResults:\nTreatment A did not significantly reduce patient distress. However, a significant decrease in sensory/psychological (P=0.027) and procedural (P=0.03) concerns, as well as prevalence and severity of and bother due to vomiting (all P=0.001), were observed at T3. In addition, subgroup analysis of patients with elevated distress at T1 indicated a significant decrease (P=0.035) at T2 but not at T3 (P=0.055) in treatment A patients.\nConclusion:\nTreatment A holds promise to improve patient treatment\u2010related concerns and some physical/psychological outcomes; however, further research is required on more diverse patient populations to ensure generalisability.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nThis study looked at how well a special education program helped cancer patients who were about to start chemotherapy, which is a type of medicine that helps fight cancer. The researchers wanted to see if this program could make patients feel less worried and help them deal with side effects like feeling sick.\n\nThey started with 192 patients but had to stop the study early because they didn\u2019t get as many people as they wanted. The patients got the education program at different times: before their first treatment, two days after their first treatment, and right before their second treatment. The researchers checked how the patients felt before the education and then again before their first and third treatments.\n\nThe results showed that the education program didn\u2019t really help reduce how worried the patients felt overall. However, it did help some patients feel less concerned about certain things, like feeling sick to their stomachs, especially by the third treatment. For patients who were really worried at the start, they felt a little better after the first treatment, but not as much after the third.\n\nIn the end, the researchers think the education program might help with some worries and side effects, but they need to do more studies with different groups of patients to see if it works for everyone. \n\nAlso, it\u2019s important to be careful when reading about studies like this because sometimes the results can be presented in a way that makes them sound better than they really are."
    },
    {
        "id": "6",
        "PMID": "21471562",
        "title": "Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial",
        "journal": "Ann Oncol",
        "abstract": "Background:\nHigh levels of distress and need for self\u2010care information by patients commencing chemotherapy suggest that current prechemotherapy education is suboptimal. We conducted a randomized, controlled trial of a prechemotherapy education intervention (treatment A) to assess impact on patient distress.\nPatients and methods:\nOne hundred and ninety\u2010two breast, gastrointestinal, and haematologic cancer patients were recruited before the trial closing prematurely (original target 352). Treatment A was administered before first treatment (intervention 1), 48 h after first treatment (intervention 2), and immediately before second treatment (intervention 3). Patient outcomes were measured at baseline (T1: pre\u2010education) and immediately preceding treatment cycles 1 (T2) and 3 (T3). The primary endpoint was psychological distress at T2 and T3 as measured by the HADS.\nResults:\nAt T2 and T3 treatment A did not significantly reduce patients distress with mean (SD) HADS scores respectively for routine care vs. treatment A at T2 10.9 (6.8) vs. 9.9 (5.8); p=0.33; and T3 10.4 (7.0) vs. 9.0 (5.8), p=0.15. There was a statistically significant decrease in sensory/psychological (P=0.027) and procedural (P=0.03) concerns, but there was no statistically significant difference between groups for the prevalence, severity and bother of most chemotherapy side\u2010effects (nausea, infection, hair loss, mouth and throat problem and fatigue) except vomiting at T3.\nConclusion:\nTreatment A was not more effective than usual care in patients commencing chemotherapy.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nThis study looked at how to help people who are starting chemotherapy, which is a type of medicine used to treat cancer. The researchers wanted to see if giving patients information and support before they started treatment would help them feel less worried or upset.\n\nThey invited 192 patients with different types of cancer to join the study. They gave some patients special help (called Treatment A) at different times before and after their first treatment, while others just got the usual care.\n\nThe researchers checked how the patients felt before and after their treatments. They found that Treatment A didn\u2019t really help reduce the patients' feelings of distress (which means feeling very worried or upset) compared to the usual care. \n\nHowever, some patients did feel less worried about certain things related to their treatment, but most of the side effects from chemotherapy, like feeling sick or tired, were about the same for both groups.\n\nIn the end, the study showed that the special help they tried didn\u2019t work better than the regular care that patients usually get when starting chemotherapy. So, they concluded that Treatment A wasn\u2019t more effective than what patients normally receive."
    },
    {
        "id": "47",
        "PMID": "22112969",
        "title": "Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer",
        "journal": "Ann Oncol",
        "abstract": "Background:\nTreatment A, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration\u2010resistant prostate cancer (mCRPC). A randomized, double\u2010blind, placebo\u2010controlled phase II trial compared DP combined with either treatment A (A) or placebo in chemonaive mCRPC.\nPatients and methods:\nMen with progressive mCRPC despite androgen deprivation were eligible and randomized 1:1. Patients received docetaxel (75 mg/m2 day 1) and prednisone 5 mg orally twice daily every 21 days with either treatment A or placebo twice daily orally on days 1\u20103. The primary end point was overall survival (OS).\nResults:\nTwo hundred and twenty\u2010one patients were randomly assigned. Median OS for treatment A plus docetaxel\u2010prednisone (ADP) and placebo\u2010DP was 18.1 versus 17.8 months [hazard ratio (HR) 1.07, 95% confidence interval 0.72\u20101.55, P=0.63]. Secondary end points were also not statistically different. Grade 3/4 toxic effects for ADP versus placebo\u2010DP were cardiac events (5% versus 2%), lymphopenia (23% versus 16%), neutropenia (47% versus 40%), ileus (2% versus 0%) and pulmonary embolism (6% versus 2%). In a subgroup of high\u2010risk mCRPC (n=34), outcomes appeared to favor ADP (median OS 19 versus 14 months).\nConclusion:\nTreatment A was tolerable but did not extend OS when combined with DP in mCRPC; a potential benefit was observed in high\u2010risk patients.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nThis study looked at a new treatment (let's call it Treatment A) for men with a type of prostate cancer that is hard to treat. The researchers wanted to see if Treatment A, when given with two other medicines (docetaxel and prednisone), would help these men live longer compared to just the two other medicines alone.\n\nThey had 221 men in the study. Some got Treatment A with the other two medicines, and some got a fake treatment (placebo) with the other two medicines. They checked how long the men lived after starting the treatment.\n\nThe results showed that the men who got Treatment A lived about 18.1 months, while those who got the fake treatment lived about 17.8 months. This means there wasn\u2019t a big difference in how long they lived. They also looked at side effects (bad reactions to the treatment) and found some differences, but nothing too surprising.\n\nIn a smaller group of men who were at higher risk, those who got Treatment A seemed to live a bit longer (19 months) compared to those who got the fake treatment (14 months). \n\nIn the end, the researchers said that Treatment A was safe to use, but it didn\u2019t really help most men live longer. However, it might help some men who are at higher risk. \n\nThe study also mentioned that sometimes people can make results sound better than they really are, so we should be"
    },
    {
        "id": "48",
        "PMID": "22112969",
        "title": "Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer",
        "journal": "Ann Oncol",
        "abstract": "Background:\nTreatment A, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration\u2010resistant prostate cancer (mCRPC). A randomized, double\u2010blind, placebo\u2010controlled phase II trial compared DP combined with either treatment A (A) or placebo in chemonaive mCRPC.\nPatients and methods:\nMen with progressive mCRPC despite androgen deprivation were eligible and randomized 1:1. Patients received docetaxel (75 mg/m2 day 1) and prednisone 5 mg orally twice daily every 21 days with either treatment A or placebo twice daily orally on days 1\u20103. The primary end point was overall survival (OS).\nResults:\nTwo hundred and twenty\u2010one patients were randomly assigned. Median OS for treatment A plus docetaxel\u2010prednisone (ADP) and placebo\u2010DP was 18.1 versus 17.8 months [hazard ratio (HR) 1.07, 95% confidence interval 0.72\u20101.55, P=0.63]. Secondary end points were also not statistically different. Grade 3/4 toxic effects for ADP versus placebo\u2010DP were cardiac events (5% versus 2%), lymphopenia (23% versus 16%), neutropenia (47% versus 40%), ileus (2% versus 0%) and pulmonary embolism (6% versus 2%). In a subgroup of high\u2010risk mCRPC (n=34), outcomes appeared to favor ADP (median OS 19 versus 14 months).\nConclusion:\nTreatment A was not more effective than placebo in metastatic castration\u2010 resistant prostate cancer patients.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\nThis study looked at a new treatment (let's call it Treatment A) for men with a type of prostate cancer that doesn't get better with regular hormone treatments. The researchers wanted to see if Treatment A, when given with two other medicines (docetaxel and prednisone), helped these men live longer compared to a fake treatment (placebo).\n\nThey had 221 men in the study. Half of them got Treatment A with the other two medicines, and the other half got the fake treatment with the same two medicines. They checked how long the men lived after starting the treatment.\n\nThe results showed that the men who got Treatment A lived about 18.1 months on average, while those who got the fake treatment lived about 17.8 months. This means there wasn't a big difference in how long they lived. They also looked at side effects (bad reactions to the treatment) and found some differences, but nothing too surprising.\n\nIn a smaller group of men who were at higher risk, those who got Treatment A seemed to live a little longer (19 months) compared to those who got the fake treatment (14 months). But overall, the study concluded that Treatment A didn't work better than the fake treatment for most men.\n\nSo, in simple terms, the new treatment didn't help men with this type of cancer live longer than the fake treatment did."
    },
    {
        "id": "13",
        "PMID": "9093724",
        "title": "Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group",
        "journal": "Ann Oncol",
        "abstract": "Purpose:\nA phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a treatment A.\nPatients and methods:\nFour hundred fifty\u2010six patients were randomized to receive either treatment A or comparator B in combination with 5\u2010FU (500 mg/m2) and cyclophosphamide (500 mg/m2) i.v., every 21 days for a maximum of six cycles (eight in case of CR).\nResults:\nOf 456 patients, 390 were evaluable for efficacy. Objective response (CR + PR) was seen in 57% (treatment A) vs. 41% (comparator B) of the evaluable patients (P = 0.003). The CR rate was higher in the treatment A arm (12% vs. 7%, P = 0.07). Treatment A produced significantly higher response rates in patients with visceral localization (50% vs. 34%, P = 0.011) and in patients with more than two metastatic organ sites (64% vs. 37%, P = 0.001). Median time to progression (7.6 vs. 7 months) and overall survival (18 months vs. 17 months) were similar. Myelosuppression was the principal toxic effect, with grade IV neutropenia observed in 57% of the patients treated with treatment A vs. 9% of those on comparator B. Grade IV infection or febrile neutropenia were observed in 8% (treatment A) vs. 0.4% (comparator B), but the incidence of septic death was the same in the two arms (two patients each). Cardiac toxicity was similar in the two treatment groups, with 5% vs. 3% of the patients taken off study due to cardiac events, primarily due to a decline in LVEF. Only three patients (two in treatment A) experienced congestive heart failure.\nConclusion:\nThis trial shows that treatment A can be administered for repeated cycles without bone marrow support with increased, though acceptable, toxicity and with a significant increase of antitumor effect (especially in visceral and/or high\u2010burden disease), but no increased survival.",
        "abstract_type": "spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose of the Study:**\nThe researchers wanted to see if a new treatment (let's call it Treatment A) helps people with a type of breast cancer that has spread to other parts of the body (called metastatic breast cancer) and if it helps them live longer.\n\n**What They Did:**\nThey had 456 patients and split them into two groups. One group got Treatment A, and the other group got a different treatment (let's call it Treatment B) along with some other medicines. They gave these treatments every three weeks for up to six times.\n\n**What They Found:**\n- Out of the 456 patients, they could really check how well the treatments worked for 390 of them.\n- More people who got Treatment A showed signs that their cancer was getting better (57%) compared to those who got Treatment B (41%).\n- Treatment A worked especially well for patients with more serious cases of cancer.\n- However, both treatments helped patients live about the same amount of time (around 18 months).\n\n**Side Effects:**\n- Treatment A caused more serious side effects, especially problems with the blood (like low white blood cells), which happened in a lot of patients (57%).\n- There were some serious infections and heart problems, but both treatments had similar rates of these issues.\n\n**Conclusion:**\nThe study showed that Treatment A can help some patients feel better, especially those with more"
    },
    {
        "id": "14",
        "PMID": "9093724",
        "title": "Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group",
        "journal": "Ann Oncol",
        "abstract": "Purpose:\nA phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a treatment A.\nPatients and methods:\nFour hundred fifty\u2010six patients were randomized to receive either treatment A or comparator B in combination with 5\u2010FU (500 mg/m2) and cyclophosphamide (500 mg/m2) i.v., every 21 days for a maximum of six cycles (eight in case of CR). The primary outcome was overall survival.\nResults:\nOf 456 patients randomized to treatment A (214) or comparator B (242), 390 were evaluable for efficacy (treatment A 182, comparator B 208). There was no statistically significant difference between the 2 groups for the primary outcome with a median survival of 18 and 17 months, respectively for treatment A and comparator B (P = 0.54). Objective response (CR + PR) was seen in 57% (treatment A) vs. 41% (comparator B) of the evaluable patients (P = 0.003). The median duration of response was 9.1 months on treatment A and 9.3 on comparator B, the median Time to Treatment Failure (TTF) was, respectively, 5.8 vs. 5.3 months (P = 0.7). Myelosuppression was the principal toxic effect, with grade IV neutropenia observed in 57% of the patients treated with treatment A vs. 9% of those on comparator B. Grade IV infection or febrile neutropenia were observed in 8% (treatment A) vs. 0.4% (comparator B), but the incidence of septic death was the same in the two arms (two patients each). Cardiac toxicity was similar in the two treatment groups, with 5% vs. 3% of the patients taken off study due to cardiac events, primarily due to a decline in LVEF. Three patients (two in treatment A) experienced congestive heart failure.\nConclusion:\nTreatment A was not more effective than comparator B in patients with metastatic breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": "Sure! Here\u2019s a simple summary of the study for your fifth grader:\n\n**Purpose of the Study:**\nDoctors wanted to see if a new treatment (let's call it Treatment A) helps people with a serious type of breast cancer that has spread to other parts of the body.\n\n**What They Did:**\nThey had 456 patients and split them into two groups. One group got Treatment A, and the other group got a different treatment (we'll call it Treatment B). Both groups also received some standard medicines every three weeks for up to six times (or eight times if they got better).\n\n**What They Found:**\n- They looked at how long people lived and how well the treatments worked.\n- Both groups lived about the same amount of time: 18 months for Treatment A and 17 months for Treatment B. This means Treatment A didn\u2019t help people live longer than Treatment B.\n- However, more people in the Treatment A group showed some improvement (57% compared to 41% in Treatment B).\n- The time before the treatment stopped working was similar for both groups.\n- Treatment A caused more side effects, especially a serious drop in white blood cells, which can make it hard for the body to fight infections.\n\n**Conclusion:**\nIn the end, Treatment A didn\u2019t work better than Treatment B for helping people live longer, even though some people did respond well to it. The study showed that Treatment A had more side effects, so it might not be the best"
    }
]